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ABSTRACT
Trefry, John Christopher. Ph.D. Biomedical Sciences Ph.D. Program, Wright State
University, 2011. The Development of Silver Nanoparticles as Antiviral Agents.

Silver nanoparticles (AgNPs) have received tremendous attention for their
antimicrobial properties; however, many gaps in knowledge exist. To address these
issues, three research objectives were examined. The first objective hypothesized AgNPs
can be size selected and concentrated via tangential flow ultrafiltration. The second
objective hypothesized a high-throughput method could be developed to screen
nanoparticle antiviral-activity and cytotoxicity simultaneously. The third objective
hypothesized AgNPs inhibit viruses by preventing viral entry.
For objective one, a tangential flow ultrafiltration scheme was tested on AgNPs
synthesized via the Creighton Colloid method. AgNPs were analyzed via transmission
electron microscopy. In objective two, an HIV-1 vector was adapted to 96-well format
and modified to utilize 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) for simultaneous cytotoxicity and antiviral measurement. The third objective was
investigated using Vaccinia virus (VACV). AgNP effects on VACV entry were
monitored through β-galactosidase reporter assay and confocal microscopy. Western
blots detected AgNP/VACV interaction. Plaque assays monitored AgNP inhibition over
the entire VACV replication cycle. MTT and trypan blue exclusion measured AgNP
cytotoxicity.

iii

In objective one, tangential flow ultrafiltration demonstrated size selection and
concentration of AgNPs. Filtered AgNPs were uniform and unaggregated with average
11 nm diameters. A high-throughput, standardized assay was developed in objective two.
AgNPs had antiviral-activity at non-cytotoxic concentrations (IC50=16 μg mL-1). In the
third objective, AgNPs prevented VACV entry in both cytoprotective and virucidal
capacities at non-cytotoxic concentrations (IC50=48 μg mL-1). In the absence of
macropinocytosis, AgNPs retained virucidal-activity but not cytoprotective effects.
AgNPs bound to viral entry proteins. Plaque assays demonstrated that AgNPs inhibited
the entire VACV replication cycle. Cytotoxicity assays demonstrated AgNPs were noncytotoxic at antiviral concentrations.
Objective one’s size selection and concentration method permits accurate
investigation into nanoparticle antimicrobial activity by eliminating size and reagent
incompatibility problems inherent to AgNP synthesis. In objective two, the traditional
viral titering assay was replaced with a standardized assay measuring simultaneously
antiviral activity and cytotoxicity, permitting faster and cheaper antiviral screening of
nanoparticles. In the third objective, AgNP-mediated antiviral-activity was pinpointed to
viral entry. Multiple mechanisms of entry inhibition were observed. These data suggest
that AgNPs can be potent and broad-spectrum antiviral agents and therapeutics.
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CHAPTER I:
INTRODUCTION
Silver
Silver has been used for millennia as an antimicrobial agent. The Phoenicians
used it to line pottery as it preserved potable goods stored within these containers (6). In
Victorian England, silver salts were used in the treatment of sexually transmitted diseases
and silver nitrate saw continued use as a disinfectant through the end of World War II
(54). After the discovery of antibiotics, however, silver was relegated to very few uses as
an antimicrobial agent. Antibiotics became preferable over silver salts because they were
significantly less toxic to the host and more effective for systemic use (6).
Silver Nanoparticles
Due to the discovery of nanotechnology, silver is making a comeback in a variety
of ways. Nanotechnology relies on the fabrication and manipulation of materials with at
least one dimension between 1 and 100 nm. Having dimensions within this particular size
window gives the material unique physical qualities. At this size, the material is too large
to be considered on the atomic/ionic scale, yet far too small to be considered bulk
material and, as a consequence, nanomaterials exhibit characteristics unlike their bulk or
ionic counterparts. For example, nanomaterials exhibit less toxicity as compared to their
ionic counterparts, yet they retain their antimicrobial activity. Compared to the bulk
materials, nanoparticles exhibit greater antimicrobial effects.
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In the case of silver nanoparticles (AgNPs), the unique characteristics associated
with the nanotechnology size window are reviving interests in developing silver as an
antimicrobial agent, in addition to more non-traditional applications. Having one
dimension between 1 and 100 nm means “naked” AgNPs, those without surface
modifications or capping agents, have an extremely large surface area to volume ratio,
thus resulting in a very low coordination number and very highly polarized surfaces (67).
Naked AgNPs bind to biological material non-specifically through their inherent need for
steric and electrostatic stabilization as a result of their highly polarized surfaces and
empty S orbital at its zero valent state (8, 46). Covalent bonds are thus easily established
with complexes containing nitrogen (amines/protein), phosphorus (phosphates/DNA) and
sulfur (thiols/protein) being common electron donors (8).
The physical traits of AgNPs can be fine-tuned using different methods to
fabricate AgNPs. Each method can impart different sizes, shapes, and surface elements,
which change AgNP reactivity (14, 50). There are many methods of AgNP synthesis, but
these methods can be broadly classified as wet or dry processes. One of the earliest
examples of wet AgNP synthesis can be found in medieval cathedrals that contain stained
glass. Although historic stained glass makers were unaware, their reduction of silver salts
created AgNPs. Different reduction techniques created AgNPs of different sizes and thus
different colors due to a property called Surface Plasmon Resonance (26). Modern wet
synthesis techniques rely on the same basic properties with much greater precision. For
example, the Creighton Colloid Synthesis method, in which sodium borohydride is used
to reduce silver nitrate into AgNPs in a water matrix, is one of the most common methods
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in use (30). Wet synthesis methods are commonly referred to as “bottom-up” synthesis
methods because AgNPs are constructed atom by atom through a nucleation process.

Figure 1. Preliminary characterization of different AgNPs. Each frame is a sample of many images
taken to characterize the AgNPs. Bar = 100 nm. A) Commercially available bottom-up biosynthetic AgNPs
with low concentration, high aggregation and high polydispersity. B) Ultraviolet radiation-based bottom-up
AgNP synthesis with high polydispersity and very low concentration C) “50 nm” commercially available
top-down synthesis AgNPs with high aggregation and possible stabilizing agent contamination D) “80 nm”
commercially available top-down synthesis AgNPs with high polydispersity and amorphous shapes. E) “10
nm” commercially available bottom-up synthesis AgNPs with observed aggregation and average 60 nm in
diameter, not the advertised 10 nm.

Dry synthesis methods of creating AgNPs are typically referred to as “top-down”
methods because they involve breaking down bulk silver into AgNPs. One common
method used today is laser ablation, where lasers are pulsed on a bulk piece of silver to
break down the large starting material into AgNPs. With current manufacturing
techniques, AgNPs synthesized in either a wet or dry synthesis demonstrate a high level
of polydispersity (16). This polydispersity was documented in preliminary data acquired
from transmission electron micrographs and subsequent particle analysis from a variety
of AgNP synthesis methods (Figure 1). These commonly used AgNP synthesis methods
were found to be too low in concentration, have high levels of polydispersity, have high
levels of aggregation and/or have highly amorphous shapes as evidenced by the images
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above (Figure 1). Each of these factors presents a problem in controlling effects of
AgNPs on a biological system. The AgNPs sampled in the preliminary characterization
were commercially available or synthesized “in-house” in efforts to find small, naked,
uniform, and monodisperse AgNPs for studies involving their antiviral properties. None
of the AgNPs in Figure 1 met these criteria. However, one commercially available AgNP
preparation, NovaCentrix 25 nm AgNPs, was small, uniform and monodisperse, so it was
chosen to carry out the research in Chapters III and IV while a technique to address the
polydispersity present in other commercially available and “in-house” AgNP preparations
is addressed in Chapter II.
Currently, commercially available AgNPs are produced, through both wet and dry
synthesis methods, and licensed for use in consumer products at an exponential rate.
Applications utilizing AgNPs have multiplied over 1,000% since 2006, with AgNPs
representing 313 of the 1317 licensed nanotechnology products (73). Most of the
commercial applications for AgNPs are antimicrobial. For example, AgNPs are
commercially available as preservatives (i.e. clothing and cosmetics), medical devices
(i.e. coatings for catheters and wound dressings), and as water treatment agents with no
defined mechanisms for their antimicrobial properties (21).
Common to all AgNP synthesis methods is the problem of generating a uniform
set of AgNPs, as shown in Figure 1 and discussed in the literature (16). Eliminating
AgNP polydispersity has been shown to increase its antimicrobial properties, possibly as
a consequence of increasing surface area and thus AgNP reactivity (3, 6). Current
technologies using both wet and dry synthesis methods produce AgNPs with a broad size
distribution, meaning the standard deviation of particle diameters is greater than 30% of
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the average diameter measurement (14). To correct for this problem, many of the
techniques used to produce AgNPs have been adapted to use additional materials during
AgNP synthesis that function to restrict particle size to a narrow distribution in the final
product. Examples of common additional agents, referred to as capping agents or
stabilizers, added to naked AgNPs, are polyvinylpyrrolidone, citrate and polyethylene
glycol. These agents have been proven biologically compatible; however, they posses
their own antimicrobial properties, which would make the identification of inherent
AgNP antiviral activity difficult (6, 39). These capping agents may even enhance toxicity
to host cells by allowing greater distribution of AgNPs in tissues, extending their half life
within the host cell or organism, or enhancing AgNP surface charges and reactivity to
augment cytotoxicity over “naked,” un-capped AgNPs (1, 22). Other organic and
chemically aggressive reagents currently used to control AgNP size, shape and dispersity
are incompatible with biological systems precluding their use in the manufacture of
antimicrobial agents (14, 50, 59, 60). To overcome the limitations of current AgNP
synthesis techniques and further investigate AgNPs as antimicrobials, a method of
purifying, size selecting, and concentrating naked nanoparticles is needed.
Silver Nanoparticles as Antiviral Agents
Very few drugs are approved as therapies for viral infection. Most of the approved
drugs are specifically designed for one species of virus and would not work in a broadspectrum capacity. The most common examples of these types of drugs are the
nucleoside analogs specific for Herpes virus infection and the neuraminidase inhibitors
available for Influenza virus infection. While extremely effective, these drugs require the
accurate identification of invading virus before prescriptions can be filled (45). Also
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associated with these drugs is an emerging pattern of antiviral drug resistance due to the
specificity in their mechanisms of action and natural selection for resistant strains (9, 56).
The pattern of antiviral drug resistance is most exemplified by chronic infections with
Human immunodeficiency virus 1 (HIV-1) and Hepatitis viruses. Current HIV-1 therapy,
highly active anti-retroviral therapy, utilizes multiple drugs to specifically inhibit
different proteins in viral replication such as the viral protease, reverse transcriptase and
integrase. Even with multiple targets, resistant viral strains still emerge due to the high
mutation rate of HIV-1 and the resultant mutants resistant to the specific inhibitors (9).
For Hepatitis virus infection, treatments were designed using broad-spectrum, nonspecific inhibitors in hopes to waylay the development of drug resistance. Interferon α,
an innate immunity protein responsible for generating antiviral responses in the body, and
Ribavirin, a suspected nucleoside analog, are used in conjunction for the treatment of
Hepatitis C virus infection (10, 13). These drugs are broad-spectrum antivirals but they
are not without their shortcomings. Interferon α therapy is associated with flu-like
symptoms, hepatotoxicity, depression, and overtime interferon resistance (13). Ribavirin
is a purine analog, not found in nature, originally synthesized in 1970. A wide range of
RNA and DNA viruses have demonstrated susceptibility to Ribavirin despite the
unknown mechanism(s) of activity. Ribavirin therapy has shown less instances of
resistance but it is also associated with high levels hemotoxocity, differences in viral
species/strain tolerance levels, and is a documented tetratogen (10). A new, broad
spectrum antiviral therapy, with no existing viral resistance is desperately needed (56).
The best defense available to viral infection was, and still is, vaccination.
However, vaccination may not be possible in cases of emerging infectious diseases, the
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deployment of biological weapons, diseases that have proven difficult for development of
vaccines, and the continued antigenic drift that can render current vaccines useless (9).
Vast amounts of time and resources are required to identify viruses and generate vaccines
with the best protection generated from pre-exposure prophylaxis (36). When a vaccine is
unavailable one could rely on the use of the previously mentioned drugs; however, due to
their specificity or associated toxicity, an accurate diagnosis must be made which takes
time. A true broad-spectrum antiviral agent, effective against many viral species/strains,
that does not require a diagnosis is greatly needed in the antiviral agent arsenal.
The antimicrobial properties of AgNPs have been evaluated for a wide range of
bacteria, viruses, and fungi (6, 53, 55). Various mechanisms for the antimicrobial
properties of AgNPs have been proposed; most of these mechanisms are based on the
suggested mechanisms for silver ion toxicity due to the same elemental composition of
AgNPs and Ag+. These proposed mechanisms include reactive oxygen species (ROS)
production, disruption of membrane potential, depletion of intracellular ATP, inactivation
of proteins, DNA damage and the production of silver ions from the AgNP surface,
which would then mediate the previously listed mechanisms (53, 55). However, each of
these mechanisms has been suggested based on evidence from AgNPs with different
characteristics such as size, shape, capping agent, and level of dispersity. No solidly
defined mechanism for AgNP antimicrobial activity is currently available.
This manuscript will focus on the antiviral aspects of AgNPs. Very little is known
concerning the mechanisms by which AgNPs exert their antiviral properties. However,
AgNPs have demonstrated antiviral activity against a number of viruses for both
prokaryotic and eukaryotic organisms, making them a true broad-spectrum antiviral
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agent. Inhibition of infection by AgNPs has been well documented for the UZ1, MS2 and
M13 bacteriophages (4, 21, 34, 68). The eukaryotic pathogens HIV-1, Herpes simplex
virus 1 (HSV-1), Herpes simplex virus 2 (HSV-2), Monkeypox virus (MPV), Hepatitis B
virus (HBV) and Tacaribe virus (TCRV) have also demonstrated a susceptibility to
AgNPs (4, 23, 32, 35, 49, 57, 58). Such broad ranges of susceptible viral species indicate
that AgNPs are an ideal candidate to be developed as a broad-spectrum antiviral agent.
In each case of viral inhibition there has been documentation of a dependence on
AgNP size for antiviral activity. One such study demonstrated that only small AgNPs, of
25 nm or less, were able to bind to the external membrane glycoprotein 120 knobs of
HIV-1, which are responsible for receptor binding (23). The mechanism for this
inhibition was proposed to be prevention of HIV-1 entry into the host cell based on
observations that AgNPs prevented syncytia formation, a late stage indicator of HIV-1
infection.
Additional studies indicated that early infection might be the general time frame
where AgNPs exert their antiviral activity which then impacts the rest of the viral
replication cycle. AgNPs are able to prevent HIV-1 CD4/gp120 mediated cell fusion,
indicating that AgNPs have the potential to inhibit virus entry; however, this study was
performed in a HIV-1 free manner where CD4 and gp120 were over-expressed in target
cells (32). HBV virus-like particles with bound AgNPs were also directly observed via
transmission electron microscopy (35). Furthermore, AgNPs inhibited MPV and HSV-2
infection as determined by plaque assay, a measurement that includes the entire viral
replication cycle (49, 57). TCRV inhibition by AgNPs was observed via quantification of
progeny genomes, an endpoint that encompasses the entire replication cycle of the virus
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(58). Generally, smaller AgNPs, less than or equal to 25 nm, have demonstrated the
greatest antiviral potential. Furthermore, each study suggested that early steps in the
infection process are the likely general time point for AgNP-mediated antiviral activity.
However, a precise mechanism of AgNP antiviral activity and precise stage of infection
at which AgNPs exert antiviral activity have yet to be determined. If a mechanism(s)
could be identified, further studies are possible regarding the antiviral development of
AgNPs to fill the vital niche of a broad-spectrum antiviral agent.
Mechanisms suggested for the antibacterial effects of AgNPs, such as ROS
production, disruption of membrane potential, depletion of ATP and DNA damage, are
downstream, long-term events that require an active metabolism that is not present in
viruses. Silver ion leaching, the suggested mechanism by which the antibacterial
activities occur, as a method of antiviral activity is unlikely as all leached ions would
quickly complex with free chlorine ions in the cellular growth medium (17). Furthermore,
Navarro et al. demonstrated that less than 1% of the silver in culture media containing
AgNPs was in the ionic form after 8 days of AgNP exposure to a synthetic growth
medium (41). While the previously mentioned mechanisms might affect host cells, these
mechanisms are unlikely to be the cause of early viral infection inhibition due to the long
exposure times required for these events. The most likely mechanism of antiviral activity,
as suggested by the literature, is AgNPs binding to viral or host proteins and inactivating
or decreasing their function at an early stage of infection.
With no specific time point identified as the target of AgNP-mediated antiviral
activity, more precise and mechanistic studies of where and when AgNPs exert their
antiviral activity are necessary. Additionally, new methods of examining AgNP-mediated
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antiviral activity are in great need. Traditional antiviral testing methods such as plaque
assays are subjective and costly due to the personnel and resources required. Highthroughput methods of detecting antiviral activity are also currently unable to distinguish
between antiviral effects, cytotoxicity and inherent characteristics of AgNPs that may
interfere with automation, such as surface plasmon resonances. Furthermore, these assays
measure the entire course of viral infection so, if viral inhibition is recorded, there is little
to no indication of how or when this inhibition might occur.
It is critical that new methods of producing and screening for antiviral activity of
AgNPs be developed because AgNPs could have significant benefits over traditional
antiviral agents. Because they are a metal they are resistant to extremes in temperature,
unlike current antiviral agents and vaccines that require temperature regulation. This
resiliency could also favor multiple methods of deployment, oral, inhalation, topical
application and even possible injection. Since AgNPs’ proposed mechanism of antiviral
activity is non-specific binding of biological molecules such as proteins, theoretically all
known viral species would be susceptible since no known viral species is devoid of
protein. While cellular proteins would also be impacted by AgNP binding, viruses could
be uniquely susceptible to AgNP binding as they are unable to regenerate damaged
proteins. The broad-spectrum activity of AgNPs would be useful for those situations were
a treatment is needed prior to a diagnosis being made or in the absence of a working
vaccine (9, 45). Traditional antivirals are demonstrating a fast emerging resistance, but
since the proposed mechanism of AgNP antiviral activity is interaction with viral
proteins, the probability of AgNP resistant viruses developing is low.
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Silver Nanoparticle Cytotoxicity
In addition to the studies performed concerning antimicrobial activities of AgNPs,
there is a growing body of research concerning their toxicity. Drawing specific
conclusions from sources of literature concerning the general toxicity of AgNPs is
difficult. Most studies utilize different sets of AgNPs with differences in size, shape,
surface elements, distribution, and synthesis methods with poor particle characterization
being a common issue. Differences in AgNP characteristics can cause markedly different
reactive properties, especially in biological systems (40). In vitro cytotoxicity values for
lethal dose 50% (LD50) in the literature range from 0.7 μg mL-1 to greater than 449 μg
mL-1 with no LD50 values reached for in vivo studies (2, 31). These differences in the
literature make the question of AgNP toxicity a difficult one to answer. A precise
mechanism responsible for AgNP cytotoxic observations has not been proposed due to
the lack of standard assays to accurately assess AgNP cytotoxicity and the lack of
experimental controls that exclude possible contamination of AgNPs with the toxic
chemicals used in their synthesis. Gaps in knowledge surrounding AgNP cytotoxicity are
critical questions to address in the development of a broad-spectrum antiviral agent as
they could potentially mask antiviral activity.
Viral Vectors
Viral vectors offer a unique platform upon which the antiviral activity of a
material such as AgNPs might be examined. At their most basic level, viral vectors are
tools for delivering genetic information into a host cell (24). What makes a viral vector
different from a wild type virus is its genetic modification to render the virus replication
deficient. This modification allows the virus to successfully infect a cell and deliver its
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genetic payload, but prevents the virus from reproducing. This functionality could be
adapted to test AgNPs and other nanomaterials for antiviral activity in high-throughput
fashion by determining whether or not AgNPs prevent the previously mentioned genetic
transfer, a measure of infection.
The most popular viral vector system is based on the Lentivirus HIV-1 (24). HIV1 is a single stranded RNA virus of the family Retroviridae. Typical wild type infection
with HIV-1 follows classical type I viral entry kinetics via specific virus/host interaction
at the plasma membrane of the cell, followed by the reverse transcription of viral RNA
and subsequent integration of proviral DNA (18). At this point the transcription of
proviral genes may then facilitate the production of progeny virions. In the viral vector
system, the genes required to produce progeny virions are not incorporated into the viral
genome, instead they are replaced with the genes to be delivered to the host cell.
Additionally, the specific HIV-1/host cell interaction required for wild type viral
infection is replaced by a viral receptor of choice. This envelope protein replacement
permits the production of viral vector particles that can simulate the infection of many
different viral species simply by utilizing their envelope proteins responsible for entry.
For example, a common envelope protein replacement for an HIV-1 vector is the switch
from HIV-1 wild type gp120 envelope protein to the Vesicular stomatitis virus G
glycoprotein (28). This swap confers broad tropism onto the vector virions instead of the
gp120/CD4 specific reaction of wild type HIV-1, which limits tropism to only those cells
expressing CD4 and appropriate co-receptors. The ability to simulate many different viral
species by interchanging the viral entry proteins would be a standardizing measure that
would greatly benefit a screening assay for nanoparticle antiviral activity.
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Vaccinia Virus
As a result of the bioterrorism attacks in 2001, the Department of Health and
Human Services has named broad-spectrum antimicrobial discovery and development a
top priority (66). The National Institute of Allergy and Infectious Disease also lists
discovery and development of therapeutics for Category A pathogens a top priority.
Variola major, an Orthopoxvirus and the causative agent of smallpox, is a Category A
pathogen and a growing concern for use in a potential biological weapon due to
decreased population immunity as a result of the cessation of vaccination.
Study of Variola major virus is highly restricted to only one location within the
United States. However, an accurate analog for the study of Variola major is available in
the form of the virus used as the vaccine for smallpox, Vaccinia virus. Vaccinia virus
(VACV), also an Orthopoxvirus, is similar enough to Variola major that exposure to
VACV offers immunity to Variola major. Due to their similarities, VACV has become
the gold standard for research on Orthopoxviruses and also for this reason, would make a
great system for the development of a rapid-response antiviral agent in the event of the
re-emergence of smallpox or the emerging disease monkeypox.
VACV is a double stranded DNA virus of about 200 kb. VACV replicates solely
in the host cell cytoplasm. The large genome encodes almost all of the structural proteins
and enzymes required to complete its replication process (19).
The infection process typically begins with VACV adsorption to the membrane of
a permissible host cell (Figure 2). This binding to the cell surface is accomplished
through VACV membrane proteins A27 and H3, D8, L1 and A26, which bind heparan
sulphate, chondroitin sulphate, and laminin respectively (15, 25, 27, 33, 47, 70). At this
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stage in the infection process the virion is bound to the cell surface but entry has not yet
occurred.
There are discrepancies in reports on the process of adsorption. Observations exist
for strain differences at the adsorption step prior to VACV entry into the host cell.
Certain strains, IHD-J, Elstree, and Copenhagen, show a high level of dependence on the
presence of glycosainoglycans (GAGs) such as heparan sulphate, while other strains,
such as Western Reserve (WR) and Wyeth, show tolerance to the absence or interference
of cellular binding factors (5). Non-GAG dependent adsorption may occur through
laminin or could be completely bypassed by virions contacting the vesicle membrane as a
result of a macropinocytotic mechanism. This variation in viral adsorption makes VACV
an ideal candidate for the development of a broad-spectrum viral entry inhibitor.

Adsorption
Direct Fusion to
Plasma Membrane

Macropinocytotic Uptake
Fusion with Vesicle Membrane

Figure 2. Ouline of VACV Infection. VACV once absorbed to its host cell can proceed via two routes to
gain access to the host cell cytoplasm. As indicated above these methods are either direct fusion to the
plasma membrane or macropinocytotic uptake, followed by fusion with the macropinocytotic vesicle.

VACV entry is dependent on a set of entry fusion complex proteins. Entry of
VACV via the entry fusion complex (EFC) has been demonstrated at both neutral and
low pH corresponding to direct fusion and macropinocytosis-dependent fusion
respectively. These differences demonstrate that VACV is capable of two distinct entry
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methods (7, 52, 69). Identified as a complex of proteins, the EFC is composed of A16,
A21, A28, F9, G3, G9, H2, I2, J5, L1, L5, and O3 with nine out of twelve of these
proteins considered integral members of the EFC as their disruption or removal
destabilizes the complex (7, 11, 29, 42, 43, 43, 44, 51, 62, 63, 65, 72). The EFC proteins
are highly conserved among all poxviruses and mutation of any of these components
yields non-infectious virions (52). The stoichiometry of the complex and its precise
mechanism of action have yet to be classified or determined (71). The EFC is theorized to
be the facilitator of virion membrane fusion with the host cell membranes for both
methods of VACV entry.
Entry into the host cell is broadly characterized as the delivery of the virion core
to the cytoplasm, regardless of how the virions are adsorbed or gain access to the host
cell cytoplasm. The viral core comes equipped with all the enzymes necessary to begin
early transcription (48). Once the viral core has entered the cytoplasm it immediately
begins to transcribe early genes (12). This process has been well documented and is
easily assayed within the first 6 hours of VACV infection via β-galactosidase expression
driven by a constitutive early/late promoter (29, 70).
One mode of VACV entry is acid mediated and dependent on viral uptake into a
macropinocytotic vesicle. VACV entry through macropinocytosis has been proposed
based on evidence that low pH treatment of bound VACV increased entry ten-fold (64).
Electron microscopy has also demonstrated VACV occupying macropinocytotic vesicles
(20). Furthermore, inhibitors of acidification drastically reduce VACV entry (61, 64).
Also, an 83% reduction in viral entry has been observed upon dominant negative
expression of Pak1, a vital component of macropinocytosis. Without this component
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there is little to no macropinocytotic uptake of virions, and the virus is not exposed to the
acidic environment of the macropinosome. The decreased infectivity as a result of Pak1
inactivation was recovered by brief acid-buffer treatment of virions attached to the
surface of the cell, supporting Pak1’s role in mediating macropinocytosis and VACV’s
macropinocytosis-dependent fusion upon exposure to the low pH environment of the
macropinosome (37).
The other mode of VACV entry is direct fusion with the plasma membrane. This
method of entry has been shown experimentally by VACV indifference to a variety of
endosomal acidification inhibitors (64). Furthermore, direct observation via electron
microscopy has shown that strains WR and Modified Ankara Virus fuse directly with the
plasma membrane (15). Also, viral membrane proteins examined via transmission
electron microscopy after immuno-labeling were found to be part of the plasma
membrane immediately after core delivery (47). This finding is indicative of the viral
membrane, and its incorporated proteins, fusing with the plasma membrane without
macropinocytotic uptake.
Based on the evidence, it seems the preferred entry method, like adsorption
method, varies from strain to strain and that each strain is capable of utilizing both
methods of entry to a certain extent. Viral strains that are highly dependent on GAGs for
adsorption could compensate by using Laminin for adsorption or instead depend more on
direct fusion with the plasma membrane. Generally, VACV strains that are tolerant to a
lack of cellular attachment factors generally depend more on macropinocytotic uptake.
However, WR, a popular research strain, has been observed directly fusing with the
plasma membrane, while other reports claim this strain is dependent on macropinocytotic
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uptake for subsequent entry into the cell cytoplasm (15, 38, 64). This discrepancy could
be the result of cell type dependent entry but suggests that this viral strain uses both entry
methods to gain access to the host cell cytoplasm. The ability to enter cells in a variety of
methods makes VACV an ideal candidate for the development of a broad-spectrum
antiviral agent.
Research Objectives and Rationale
In order to address the previously mentioned gaps in knowledge surrounding the
biological applications of AgNPs, three research objectives were identified. Each
objective was designed around a central hypothesis. Furthermore, each objective’s
hypothesis was investigated via a set of specific aims designed to fully explore the gaps
in knowledge of each respective field.
The first objective hypothesized that highly concentrated, highly homogenous,
non-aggregated AgNPs can be size selected and concentrated via tangential flow
ultrafiltration. This hypothesis manifested from the lack of accurate methods capable of
producing AgNPs free of contaminants from their synthesis, with limited polydispersity
and without the use of capping or stabilizing agents. To test this hypothesis specific
research aims were established.
The first aim sought to develop a tangential flow ultrafiltration scheme capable of
size selecting and concentrating AgNPs synthesized via Creighton method. This aim
addressed the issues surrounding the production of AgNPs with limited polydispersity in
the absence of capping or stabilizing agents that may interfere with the use of AgNPs as
antimicrobial agents. The second aim examined the relative size selection and
concentration effectiveness between the newly developed tangential flow ultrafiltration
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scheme and the commonly used ultracentrifugation method for the size selection and
concentration of AgNPs.
The development of more precise and higher-throughput methods for examining
the antiviral activity of AgNPs was the focus of the second research objective. Because
traditional plaque assays are subjective and require large amounts of time and money, a
quicker high-throughput format for screening antiviral activity is desirable. Additionally,
current techniques rely on performing cytotoxicity assays separately from the antiviral
testing. This separation can result in the masking of antiviral activity by cytotoxicity.
This objective also addressed the need for standardization of antiviral testing between
viral species, since current methods require separate assays for different viral species.
To address the issues surrounding the second objective, three research aims were
developed. The first aim sought to adapt a large scale screening technique for HIV-1
mutation rate, utilizing a viral vector system, to a small-scale, high-throughput format
designed to assess viral titer. Aim two of this objective characterized the ability the novel
assay format to accurately assess viral titer compared to the original colony forming unit
assay. The third aim of the second objective was to determine the assay’s ability to
simultaneously chart antiviral activity and cytotoxicity.
The third objective hypothesized that AgNP mediated antiviral activity was the
result of AgNPs preventing viral entry. This objective would pinpoint the stage of viral
infection at which AgNP antiviral activity occurs and illuminate possible mechanisms
behind this inhibition, a vital gap in knowledge concerning AgNP antiviral activity.
VACV was chosen as the viral system to examine AgNP-mediated antiviral activity and
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its possible mechanisms due to the call to research by various governmental agencies and
the growing concern for the use of Variola major as a potential bioweapon.
The third objective’s hypothesis would be investigated through three specific
aims. The first aim sought to investigate the effects of AgNPs on the adsorption of
VACV to host cells. Determination of AgNP effects on overall VACV entry was
addressed in the second aim of this objective. Finally, the third aim examined the effects
of AgNPs on the direct fusion entry pathway of VACV, in the absence of
macropinocytosis.
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ABSTRACT
A proposed tangential flow ultrafiltration method was compared to the widelyused ultracentrifugation method for efficiency and efficacy in concentrating, size
selecting and minimizing the aggregation state of a silver nanoparticle (AgNP) colloid
while probing the AgNPs’ SERS-based sensing capabilities. The ultrafiltration method
proved to be more efficient, more effective and was found to tremendously boost the
SERS-based sensing capabilities of these AgNPs through the increased number of
homogenous SERS hot spots available for a bio-target molecule within a minimal focal
volume. Future research studies and applications that address the physiochemical
properties or biological impact of AgNPs would greatly benefit from ultrafiltration for its
ability to generate monodisperse colloidal nanoparticles, to eliminate excess toxic
chemicals from nanoparticle synthesis and to generate minimum levels of aggregation
during nanoparticle concentration.
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INTRODUCTION
Silver nanoparticle (AgNP) preparation and manipulation is an extremely active
research area due to the numerous applications of these nanomaterials to catalysis,
photonics, electronics, biosensing, drug delivery, pharmaceuticals, etc.1 One of the most
exciting and demanding applications of AgNPs is their surface-enhanced Raman
spectroscopy (SERS)-based biosensing capability. SERS is a powerful analytical
technique used to detect specific molecular vibration modes, which has experienced an
explosive interest due to its strong molecular specificity and its extremely low detection
limits, down to the single-molecule level.2a,b Theory predicts2c,d and experiments
confirm2a,b,

1c

that exceptionally large increases in Raman cross-section, or signals

attained through Raman spectroscopy, are associated with molecules located in the nanosized interstitial sites of interacting colloidal AgNPs (i.e. hot spots).
Significant challenges remain for the preparation and isolation of colloidal AgNPs
with controlled polydispersity, toxicity and aggregation. Limiting AgNP polydispersity
(i.e., narrow size and shape distribution)3a improves the optical/electronic properties,2c,d, 3a
SERS enhancement factors, or increases in Raman signals corresponding to the presence
of an enhancement material,2c,d and antimicrobial properties.1e 3f Reducing AgNP toxicity
by eliminating chemically aggressive reagents or organic solvents3a,c significantly lowers
the impact to biological systems, while facilitating the identification of novel activities
and mechanisms.1e,

3c-e

Minimizing AgNP aggregation at higher concentrations1c,

3a,c

allows the assessment of SERS nanostructure-function relationship,2c,d improves the
cellular uptake of AgNPs1c, 3d-f and maintains the number of potentially active catalytic
sites.1a Additionally, use of methods such as centrifugation,4a size exclusion
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chromatography,4a,b gel electrophoresis,4c diafiltration,4d size-dependent solubility4e and
fractional crystallization4f have been reported for the size-based separation and/or
concentration of NPs. These approaches may lead to issues with aggregation,4a
instability,4a cost,4b,

4e

undesired coatings,4c

4f

and less effective protocols for NPs of

smaller size.4f As a result, these methods are time intensive, expensive, toxic or
inefficient.4 These limitations were overcome in this study by using a tangential flow
ultrafiltration method, commonly used for weight-based separation of proteins, but not
yet tested on silver or polydisperse colloids.4d This method relies on passing a fluid
through a hollow fiber with specific pore sizes, allowing the solvent to pass through the
pores and retaining solutes possessing sizes larger than the pore size within the hollow
fiber. Tangential flow ultrafiltration is a single pass procedure to size select and to
concentrate a target species using a series of membrane-modules with pores ranging from
1 nm to 100 μm. The proposed method was compared to the widely-used
ultracentrifugation method for efficiency and efficacy in concentrating, size selecting and
minimizing the aggregation state of an AgNP colloid while probing the AgNPs’ SERSbased sensing capabilities.
RESULTS AND DISCUSSION
Colloidal AgNPs were synthesized according to a well-known, inexpensive
Creighton method by the simple reduction of silver nitrate with sodium borohydride.
Once synthesized, the 600 mL original colloid (Ori) product was divided into two
aliquots for the comparative analysis. Ultracentrifugation was performed at 7.8 x 103 g
and 10°C for 90 min to separate the colloid into a supernatant (Csu) and a pellet (Cpl) of
AgNPs. Cpl was resuspended in 10 mL of supernatant. For ultrafiltration, the colloid was
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pumped through a 50 nm filter yielding a concentrate (50c; AgNPs > pore size) and a
filtrate (50f; AgNPs < pore size) sample. The 50f sample was then pumped through a 100
kD filter to produce a concentrated (100c) sample (Figure S1).
Visual inspection, transmission electron microscopy (TEM), UV-Vis absorption,
and flame atomic absorption spectrophotometry (FAAS) measurements on each sample
revealed corroborating data that the ultrafiltration method was more efficient at specific
size selection and concentration of AgNPs with minimal aggregation than
ultracentrifugation (Fig. 1A, Table 1). The dramatic color change between Ori, Cpl, and
100c confirms that darker, more opaque solutions contain larger particles with high levels
of AgNP aggregation (Fig. 1A, column 1).5a, TEM micrographs (Fig. 1A, column 1)
show that Ori is characteristic of moderately dispersed, lowly concentrated AgNPs. Cpl
contains high concentrations of massive, heterogeneous AgNP-aggregates. 100c consists
of highly concentrated yet lowly aggregated and homogenous AgNPs. The UV-Vis
spectra show both Ori and 100c samples had surface plasmon resonance (SPR)
absorption maximums at 400 nm, but 100c had a 10-fold higher intensity. This sharp,
symmetrical peak is characteristic of small (10-20 nm diameter) and spherical AgNPs of
low aggregation.5c,d The spectra for Cpl had a broader SPR peak with a clear shoulder,
showing the ultracentrifugation process leads to the formation of polydisperse AgNPaggregrates.
Size histograms (Fig. 1A, column 2) were prepared by analyzing the TEM
micrographs of each sample (number of AgNPs = 500). The differences in size
distribution and maximum diameters for the Ori and Cpl samples are significant (e.g.,
more than twice for Cpl) in comparison to the 100c sample. Most of the aggregates larger

37

than 20 nm were eliminated in 100c (Fig. 1, column 2), while Cpl had increased numbers
of larger aggregates (5% of the total AgNPs have diameters 50 nm or larger). These large
aggregates produced by ultracentrifugation accounted for 96% of the AgNP weight.
Ultrafiltration was also 2.5-fold more efficient at concentrating the Ori colloid (from 77.4
to 198.7 μg mL-1 of silver). Concentration factors for Cpl and 100c were 5.1- and 13.0fold, respectively (Table 1).
Sample Ori

Csu

Cpl

50c

11.4 18.2

50f

100c

3.3

11

Ave.

10.4 8.5

Max.

141

54.4 161

162.5 87.3 60.5

%Dist.

100

106

129

Conc.

15.3 7.9

162

77.4 16.4

127

73

14.3 198.7

Table 1. Specific characteristics of each AgNP preparation. Average size in nm (Ave.), maximum size
in nm (Max.), percent distribution (% Dist.), final concentration of silver in µg mL-1 (Conc.).

The SERS-sensing efficiencies, the analytical (AEF) and surface enhancement
factors (SEF), of Ori, Cpl and 100c were calculated by measuring the Raman, SERS, and
fluorescence spectra of a 10-6 M rhodamine 6G (R6G) solution as a standard (Fig. 1B;
Supporting Info).5c The AEF and SEF for Cpl and 100c were found to have similar values
(e.g., AEF of 8.1 x 107 and SEF of 7.9 x 104 for 100c). These factors are 1,000-fold larger
than those calculated for Ori. Recent studies5c showed that a SEF of 107 is sufficient to
observe single-molecule SERS events for a R6G concentration of 10-9 M, at 632.8 nm,
and with an integration time of 1s. The fluorescence data indicate that 100c and Cpl have
comparable, improved R6G absorption abilities. Over 96% of the R6G molecules
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effectively complexed to the AgNP surface and contribute to the SERS signal in 100c and
Cpl (70% of the R6G probes for Ori). The enormous increase in signal for 100c is due to
the highly concentrated, uniform colloidal AgNPs available for creating dimers or small
AgNP-aggregates. Although the amount of silver is 2.5-fold less in Cpl, similar
enhancement factors are achieved due to the large, heterogeneous AgNP-aggregates.
However, the Cpl aggregates are formed in an uncontrolled manner and may impede
cellular uptake and assessment of nanostructure-function relationship.
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A Original Colloid

B

Ultracentrifuged

Ultrafiltered

Figure 1. AgNPs were characterized at each step in the isolation and concentration process. A) Each row
represents a distinct preparation: column 1) visual and TEM inspection photos, bar = 100 nm, column 2)
size analysis from TEM data, and column 3) UV-Vis absorption spectra. B top) SERS spectra of R6G dye
(10-6 M) for each colloid. B bottom) Estimated analytical (AEF) and surface enhancement factors (SEF) for
each colloid.
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The data presented here demonstrate that ultrafiltration permits greater control
over AgNP size, concentration and aggregation state than conventional methods of
isolation such as ultracentrifugation. Future research studies and applications addressing
the physiochemical properties or biological impact of AgNPs would greatly benefit from
ultrafiltration for its ability to generate monodisperse colloidal NPs, to eliminate excess
toxic chemicals from NP synthesis, and to obtain minimum levels of aggregation during
NP concentration. The ultrafiltration method for AgNP isolation could tremendously
boost the SERS-based sensing capabilities of these nanomaterials through the increased
number of homogenous SERS hot spots available for a bio-target molecule within a
minimal focal volume. Additionally, ultrafiltration could easily be implemented at
various volume scales, for both research and industrial purposes.
Supporting information available: Experimental methods and AEF/SEF calculations are
available at http://pubs.acs.org.
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MATERIALS AND METHODS
Abbreviations
R6G – rhodamine 6G; Colloidal Samples: Ori – Original, Csu – Ultracentrifuged
supernatant, Cpl – Ultracentrifuged, 50f – 50 nm Ultrafiltered filtrate, 50c – 50 nm
Ultrafiltered concentrate, and 100c –100kD Ultrafiltered.
Experimental section
All starting materials were purchased from commercial sources as analytical pure
reagents.
Chemicals and procedures
Colloidal silver nanoparticles (AgNPs) synthesis
A slightly modified Creighton1 colloid was produced by the borohydride
reduction (NaBH4, Fisher Scientific) of silver nitrate (AgNO3, Fisher Scientific). Briefly,
an AgNO3 solution (1.70 mg in 10.0 mL of highly purified water) cooled to
approximately 10±2°C was added drop wise, with constant stirring, to a NaBH4 solution
(4.53 mg in 60.0 mL of highly purified water) pre-cooled to 2±1°C. Stirring was
continued for another 50 min in the ice bath. The colloid was then stored in refrigerator at
4±1°C until use.
Theoretical estimate of the amount of colloidal AgNPs
In preparing the colloid, 1.70 mg of AgNO3, corresponding to 10-5 mols, were
added to 10.0 mL of water and slowly mixed with 60.0 mL of a NaBH4 solution.
Therefore, the final volume of colloid (70.0 mL) had a total silver mass of 1.08 x 10-3 g.
Thus, the amount of silver per milliliter of colloid is 15.42 µg mL-1.
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Instrumentation
Sample Preparation
Freshly synthesized AgNP suspensions were passed through 0.2 μm filters prior
to purification (Nalgene Labware). A 300 mL volume of these pre-filtered AgNPs, which
was obtained by combining several batches, was then used for processing by
ultracentrifugation and tangential flow filtration methods.
Ultracentrifugation
All centrifugation was performed in a L8M-70 ultracentrifuge using a 45-Ti fixed
angle rotor and a 70 mL bottle with cap assembly (Beckman Coulter). Samples were
centrifuged at 10 °C, for 90 minutes at 7.8 x 103 g (10,000 rpm). Supernatants were
removed using serological pipets. While decanting the supernatant, 10 mL were left
within the centrifuge bottle. This remaining supernatant was used to resuspend the AgNP
pellet. The ultracentrifugation scheme is represented in Figure S1.
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Figure S1. A schematic representation of the overall size selection and concentration processes. Samples
taken at each step in the process are represented in boxes. Labeled arrows indicate the specific size
selection and concentration step.

Tangential Flow Filtration
The filtering apparatus and equipment was assembled according to the
manufacturer’s recommendations (Spectrum Laboratories, Rancho Dominguez, CA).
Samples were filtered through a 50 nm Midi Kros module at a steady flow rate of 300 mL
min-1 using the KrosFlo II Research System. The resulting filtrate’s volume, containing
particles smaller than 50 nm (50f), was further filtered through a 100 kD Midi Kros
module, while the concentrate volume (system holdup volume of 10 mL) was saved for
analysis. The 100 kD filtrate, containing particles smaller than 100 kD (100f), and
concentrate, containing particles larger than 100 kD (100c), volumes were likewise
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retained for analysis. The filtering scheme is represented in Figure S1. Tubing and
reservoirs were replaced or cleaned by washing three times with de-ionized water and 7x
detergent (MP Bio), followed by three flushes of de-ionized water, between each filtering
step.
UV-Vis absorption spectrophotometry
The absorption spectra, corresponding to innate surface plasmon resonances of
AgNPs which indicate AgNP size and dispersity in solution, were recorded using an 8453
UV-VIS-NIR (Hewlett Packard Inc.) spectrophotometer and a Cary 50 UV-VIS-NIR
spectrophotometer (Varian Inc.) at 1 nm intervals. Each colloidal AgNPs sample was
diluted with highly purified water (1:10 volume ratio) before measurement. A cell (Fisher
Scientific) of a path length of 10.0 mm and a capacity of 4.5 mL was used for all
measurements.
Transmission Electron Microscopy (TEM)
Samples were diluted in highly purified water when necessary. Twenty
microliters of each sample were then deposited on 300-mesh formvar-coated gold grids
(Electron Microscopy Sciences). Grids were left to dry in a desiccator and viewed within
one day. A Phillips EM 208S transmission electron microscope operating at an
accelerating potential of 70kV was used to visualize the nanoparticle samples before and
after each step of the purification process. Electron micrographs were captured using a
high resolution Gatan Bioscan camera.
TEM image analysis
Tagged image files were analyzed by ImagePro software (Media Cybernetics
Inc.). Automated count settings were used to distinguish the light background from the
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dark perimeter of the AgNPs. One particle was defined by a complete and enclosed
perimeter. A minimum of 500 particles per sample were analyzed. The Microsoft Excel
software was then used to bin and analyze the average particle diameter data collected
from the micrographs. The Origin 8 software was then used to graphically represent the
data.
The average particle diameters for 50f and 100c were 3.3 nm and 11 nm,
respectively. (Table 1 of the manuscript) This corresponding increase in average particle
diameter is due to the increased counting frequency of particles with sizes between the
upper and lower filter limits and the reduction in frequency of the smaller particles due to
their passage through the filter. The larger particle frequency is increased due to large
particle retention within the lumen of filter module. Concurrently there is a decrease in
small particle frequency from their passage through the membrane and into the eluent or
filtrate. Additionally, the maximum diameter of 60.5 nm for 100c was unexpected for the
filter limit of 50 nm. In theory, all of the particles with diameters larger than 50 nm
should have been removed from the 50f sample by their retention in the 50 nm filter.
However, particles with maximum diameters larger than 50 nm can still exist in the 50f
sample because they may be slightly non-spherical and have other dimensions less than
50 nm allowing them to pass through the filter in the first filtering scheme (50 nm filter),
but be retained in the second step (100 kD filter). This explanation applies to the 50f
sample as well.
Flame Atomic Absorption Spectroscopy (FAAS)
An AA reference silver standard solution of 1.0 x 103 µg mL-1 was purchased
from Fisher Scientific (Lot Number: CL4-132AG) and used for the preparation of six
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silver standards of 0.1, 0.2, 0.5, 1.0, 2.0, and 4 µg mL-1. The FAAS calibration curve is
depicted in Figure S2. Each sample contained 2% nitric acid (Optima grade, Fisher
Scientific, Catalog #A467-500). Samples were diluted 100x (Ori, Csu, 50f) or 200x (Cpl,
50c, 100c).

Figure S2: Flame atomic absorption spectroscopy calibration curve constructed by using six silver
standards of 0.1, 0.2, 0.5, 1.0, 2.0, and 4 ppm.

A fast sequential atomic absorption spectrometer (model AA240 FS, Varian Inc.)
equipped with an air-acetylene burner and a silver hollow cathode lamp (5 mA) was used
for the determination of silver content within samples. The operating conditions were set
as recommended by manufacturer: wavelength - 328.1 nm, slit width – 0.5 nm, air flow
rate – 13.50 L min-1, and acetylene flow rate 2.00 L min-1. The acquisition time of each
measurement was 5 s, and a delay time of 3 s was introduced in between measurements.
Each sample was measured three times and the absorbance values were averaged before
extrapolating the silver concentration from the calibration curve. A blank solution was
introduced between each sample.
Raman and SERS Spectroscopy
A 10-3 M stock solution of the rhodamine 6G dye (R6G, Fisher Scientific) was
prepared in water and further diluted to the desired concentrations. The SERS samples
were obtained by adding 0.9 x 102 µL of the 2.22 x 10-6 M R6G solution and 0.1 x 102 µL
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of the 1 M KBr (Fisher Scientific) solution to 1 mL of each of the colloidal samples (i.e,
Ori, Csu, Cpl, 50c, 50f, and 100c). The final concentrations of KBr and R6G in the
colloidal suspension were approximately 0.5 x 10-1 M and 10-6 M, respectively.
The Raman and SERS measurements were performed using a LabRamHR 800
system (Horiba Jobin Yvon Inc.) equipped with 1800 and 600 grooves/mm holographic
gratings. The 633 nm output of a He-Ne laser was used as an excitation line. The laser
output was 17 mW. The laser beam spot had a diameter of about 1 µm and was focused
on the colloidal samples placed in cuvettes with the help of a high resolution confocal
Raman microscope (high stability BX41) and a long working distance Olympus objective
(50x). The confocal hole was set at 300 µm and the backscattered Raman signal was
recorded using an open electrode thermo-electric cooled CCD detector (1024x526
pixels). The spectral resolution was 1 cm-1. The acquisition times were a) 30 s for normal
Raman measurements and b) 3 s (all samples except for 100c and Cpl) or 0.5 s (100c and
Cpl) for SERS spectra. Each Raman and SERS spectral window was averaged over 3 and
5 cycles, respectively. The Raman data were then analyzed and processed using the
LabSpec 5 and Origin 8 software. A comparative graph showing the SERS spectra of Ori,
Cpl, and 100c was prepared for Figure 1 of the manuscript after rescaling the intensities
in the SERS spectrum of the original colloid (Ori) to compensate for the different
acquisition times (3s for Ori and 0.5 s for 100c and Cpl). In this graph, the SERS spectra
of Cpl and 100c were shifted on the Y scale (Raman Intensity) to allow for a direct
comparison of peak intensities.
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Fluorescence Spectroscopy
The fluorescence emission spectra of all SERS samples and R6G solution (0.75 x
10-6 M) were recorded in a fluorescence quartz cuvette using a Cary Eclipse fluorescence
spectrophotometer (Varian Inc.). The 10-6 M solution of R6G caused detector saturation
and could not be recorded. The excitation wavelength was 532 nm and the emission
spectra were collected in the 540-700 nm range using a PMT detector voltage of 600 V at
a scan rate of 600 nm min-1.
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Figure S3. Overview of colloidal AgNP processing and characterization. AgNPs were characterized at
each step in the ultracentrifugation (Csu and Cpl) and ultrafiltration (50c, 50f, and 100c) process, and
compared with the original colloid (Ori). Each row represents a distinct preparation step: column 1) sample
name, column 2) visual and TEM inspection photos, bar = 100 nm, column 3) size analysis of AgNPs from
TEM data, column 4) UV-Vis absorption spectra, column 5) Raman (at 10-3 M) and SERS (at 10-6 M)
spectra of R6G (The ordinary Raman spectrum of each colloidal sample was inserted as a control), and
column 6) fluorescence emission spectra of each colloidal sample incubated with R6G at 10-6 M before and
after centrifugation (supernatant) at 7.8 x 103 g and 10°C for 90 min (The fluorescence emission spectrum
of R6G at 0.75 x 10-6 M was inserted for comparison reasons).
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Analytical Enhancement Factor (AEF) and Surface Enhancement Factor (SEF)
Estimates
The AEF and SEF are the most important values for characterizing the SERS effect.
The peaks at 1652 cm-1 of R6G (i.e., a streching of the R6G xanthine ring) and 32503420 cm-1 of H2O (i.e., two broad bands corresponding to the symmetric and asymmetric
water stretching modes) were chosen to estimate these factors using an excitation line of
632.8 nm.2,3 After a baseline correction (User defined baseline anchor points: 10 points,
Interpolation method: Bspline), the ratio of the integrated peak areas at 1652 cm-1 and at
3380 cm-1 was determined for both, the Raman and SERS spectra of R6G (e.g.,

Int. area R6G, Raman / Int. area H 2O , Raman = 2.26 × 10 4 / 2.06 × 10 6

for

the

normal

Raman

spectrum of the 10-3M R6G solution). The non-SERS differential Raman cross-section of
R6G ( dσ R6G, Raman / dΩ ) was included to obtain reliable and realistic enhancement factors.
This aspect has often been ignored and is partially responsible for the unrealistically large
enhancement factors sometimes reported in literature. Dyes such as R6G can have
notably large differential Raman-cross sections2 even in non-resonance conditions due to
pre-resonance effects2,3. The R6G dye has an absorption maximum at 528 nm and the
excitation wavelength employed in this study was 632.8 nm.
The non-SERS differential Raman cross section of R6G ( dσ R6G, Raman / dΩ ) was
determined using the following formula:
dσ R6G, Raman / dΩ
dσ H 2O , Raman / dΩ

=

Int. area R6G, Raman / C R 6G , Raman
Int. area H 2O , Raman / C H 2O , Raman

(1)
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where dσ R6G, Raman / dΩ and dσ H 2O, Raman / dΩ ( 2.2 x 10 −30 cm 2 sr −1 )3 are the differential
normal Raman cross-sections of R6G and H2O, respectively, excited at 632.8 nm.
C R 6G , Raman (10-3 M) and C H 2O , Raman (55.5 M) denote the molar concentrations of R6G and

water, respectively.
In this study, a non-SERS differential Raman cross section of 1.3 x 10 -27 cm 2 sr −1
was obtained for the peak at 1652 cm-1 of R6G which agrees well with the one reported
in literature.3 Although this cross-section is much larger than the value which Nie et al.
had estimated in his single-molecule SERS study,4 it is similar to the experimental results
in the literature ( 4.4 x 10 -27 cm 2 sr −1 ).2,3 The differential Raman cross-section of R6G at
resonance was recently predicted to be on the order of 10 -25 cm 2 sr −1 .3,4 The large
differential Raman cross section of R6G at λ0 = 632.8 nm is partially due to the
relatively large size of the R6G molecule, but above all, it is the result of the preresonance Raman effect (the excitation wavelength is close to the resonance
wavelength).2,3
A similar approach was used to calculate the differential SERS cross-section of
R6G (e.g., dσ R6G, SERS / dΩ = 9.746 x 10 -24 cm 2 sr −1 for Ori) at an analyte concentration,
C R 6G , SERS , of 10-6 M foreach colloidal suspension (i.e., Ori, Cpl, and 100c). The water

concentration, C H 2O , Raman , was maintained the same as for the normal Raman
experiments.
The AEF factor indicates how much more signal can be expected from SERS as
compared to the normal Raman under the given conditions.
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AEF =

dσ R 6G , SERS / dΩ acq. timeRaman
x
dσ R 6G , Raman / dΩ acq. timeSERS

(2)
The different acquisition times for the Raman and SERS measurements of Ori, Cpl, and
100c were also factored into the above formula (e.g., 30s/3s for Ori). All other
experimental conditions were identical (i.e., microscope objective, lenses, spectrometer,
cuvette, etc.) The values obtained for each colloidal sample are listed in Table S1.
Although C R 6G , SERS does not fully characterize the number of R6G molecules
adsorbed AEF is useful for specific practical applications (e.g., colloidal solutions). The
AEF factor strongly depends on many parameters, in particular, on the adsorption
properties and surface coverage of the dye probe. The AEF formula ignores that only the
adsorbed probe molecules contribute to the SERS signal and that the enhancement effect
is distance-dependent. Hence, the AEF factor does not offer a good characterization of
the SERS substrate itself and it cannot be used to an absolute comparison term for the
performance of different SERS substrates. AEF does represent a simple figure for SEF
provided that submonolayer coverage is ensured.
The absorption ability of the Ori, Cpl, and 100c colloidal samples towards the R6G
probes were estimated in this study using fluorescence quenching experiments. It should
be mentioned here that only the free R6G molecule in the colloidal suspension are able to
contribute to the fluorescence intensity. The colloidal samples alone and their
corresponding supernatants after the centrifugation process exhibited the same
fluorescence intensities.
The fluorescence emission spectra in Figure S3 show that the Ori, Cpl, and 100c
colloidal samples incubated with R6G at a 10-6 M concentration present a significant
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decrease in fluorescence intensity ( I R 6G in colloid ) in comparison with their corresponding
supernatants collected after ultracentrifugation ( I R 6G in colloid supernatant ). The decreased
intensity is due to the inability of R6G molecules to fluoresce because of their absorption
on the AgNP surface. As expected, dramatic fluorescence intensity reductions were
noticed for Cpl and 100c due to the increased number of AgNPs available to adsorb the
R6G dye molecules within the same volume when compared to Ori. The actual number
of R6G molecules ( CR 6G on AgNP surface ) contributing to the observed SERS enhanced signal
(Table 1) was calculated using equation (3) based on the observed changes in intensity
and the fluorescence intensity of the R6G bulk solution ( I R 6G bulk solution ) as a reference. The
difference in concentration for the R6G solution in the bulk solution (0.75 x 10-6 M) and
the colloid (10-6 M) was also factored in.
C R 6G on AgNP surface = 10 − 6 M x (100% -

I R 6G in colloid − I R 6G in colloid supernatant
I R 6G bulk solution

x

0.75x10 -6 M
x 100%)
10 -6 M

(3)
The SEF factors were then determined according to the following equation:
SEF
C R 6G on AgNP surface

=

AEF
C R 6G in bulk solution

(4)
where CR 6G on AgNP surface and CR 6G in bulk solution are the number of R6G molecules on the
AgNP surface and in the bulk solution, respectively.
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Sample

% of R6G molecules

AEF

SEF

contributing to SERS signal
Ori

70

7.3 x 104 5.1 x 101

Cpl

97

7.0 x 107 6.7 x 104

100c

96

8.1 x 107 7.9 x 104

Table S1. Analytical (AEF) and surface (SEF) enhancement factors estimated at an R6G analyte
concentration of 10-6 M and an excitation wavelength of 632.8 nm.

REFERENCES for MATERIALS AND METHODS

1. Creighton, J.A.; Blatchford, C.G.; Albrecht, M.G. Plasma resonance enhancement of
Raman scattering by pyridine adsorbed on silver or gold sol particles of size
comparable to the excitation wavelength J. Chem. Soc., Faraday T. 2, 1979, 75, 790798.
2. Ru, E.C.; Blackie, E.; Meyer, M.; Etchegoin, P.G. Surface Enhanced Raman
Scattering Enhancement Factors: A Comprehensive Study J. Phys. Chem. C. 2007,
111, 13794-13803.
3. Ciou, S.H.; Cao, Y.W.; Huang, H.-C.; Su, D.Y.; Huang, C.L. SERS Enhancement
Factors Studies of Silver Nanoprism and Spherical Nanoparticle Colloids in The
Presence of Bromide Ions. J. Phys.Chem. C 2009, 113, 9520-9525.
4. Nie, S.; Emory, S. R. Probing Single Molecules and Single Nanoparticles by SurfaceEnhanced Raman Scattering. Science 1997, 275, 1102-1106.

57

CHAPTER III
A High-throughput Screen for Nanotechnology-based Antiviral Agents as Demonstrated
with Silver Nanoparticles

ABSTRACT
Nanotechnology offers untapped potential into the development of novel antiviral
agents; however, no technology exists to screen these new materials for antiviral activity
in a high-throughput format. To address this issue a new assay was developed that
combines a cellular proliferation assay with a viral vector system to simultaneously
measure antiviral activity and cytotoxicity of nanomaterials. Silver nanoparticles,
currently generating broad interest and increasing commercial presence as antimicrobials,
were chosen to test the new assay’s ability to measure antiviral activity in addition to
charting the new assays sensitivity in parallel with traditional methods. This new assay
was sensitive to viral inhibition spanning 99% of the infectious titer generated with the
viral vector system. Significant antiviral activity of silver nanoparticles was observed at
doses as low as 2 μg mL-1, while cytotoxicity was found only at doses≥ 500 μg mL

-1

,

without reaching the LD50. These results reveal a sensitive and innovative method for
determining the antiviral activity of nanomaterials in a small-scale, high-throughput
manner.
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INTRODUCTION
Nanotechnology is currently a hotbed of interest for the development of
commercial applications, in particular the discovery of novel antimicrobial agents. Many
different nanomaterials have demonstrated innate antibacterial activity but little research
exists on their antiviral potential. An explanation for the understudied antiviral properties
of nanomaterials stems from the lack of established methods to screen the antiviral
activity of nanomaterials, especially in a high-throughput format.
Defined as having one dimension between 1 and 100 nm, nanomaterials are
characteristically distinct from their bulk and ionic counterparts due to their large surfaceto-volume ratios and unique reactivities. Silver nanoparticles (AgNPs), in particular, were
chosen for the current study because they have demonstrated antimicrobial properties (5,
15, 21, 22). Silver, in its ionic form, has been used as an antimicrobial for millennia with
little known resistance, and the emergence of nanotechnology has generated new interest
in the development of silver as a potent antimicrobial in the post-antimicrobial resistance
era. AgNPs are gaining critical attention due to their ever-increasing commercial
presence, despite the unknown mechanisms for their antimicrobial action and potential
for cytotoxic effects (7, 10, 17, 23).
In order to accurately gauge the potential of nanomaterials as an antiviral agent, a
new assay was successfully developed to measure inhibition of viral infection while
simultaneously charting the toxicity of the nanomaterial itself. Traditional colony
forming unit (CFU) assays for viruses, based on the transduction of a selective marker
through a non-lytic virus, are cumbersome and impractical for screening large numbers of
drugs at multiple doses. The new assay, based on the standard 3-(4,5-dimethylthiazol-2-
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yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay employs a highthroughput, small-scale format that will be more efficient and economical, thus enabling
more in depth investigations of nanomaterials as antiviral agents.
MATERIALS AND METHODS
Nanoparticle Characterization
Spherical, 25 nm diameter AgNPs were used (NovaCentrix, Austin, TX). The
AgNPs were 99.9% pure silver as determined by induction-coupled plasma spectroscopy
performed by NovaCentrix. Transmission electron microscopy (TEM) was conducted to
confirm size and morphology using a Philips EM 208S operating at 70kV (Royal Philips
Electronics, NL; Fig. 1A). AgNPs were negatively stained with 3% uranyl acetate to test
for organic capping agents or impurities bound to the particles’ surfaces (Fig. 1B).
Analysis of TEM images was accomplished using Image-Pro 6.2 software (Media
Cybernetics, Inc., Bethesda, MD). Specifically, size measurements were performed by
allowing the software to automatically define the perimeter of each nanoparticle, and then
calculate the average of multiple diameter measurements for each particle. Prior to use in
viral inhibition assays or particle characterization, AgNPs were sonicated for 30 seconds
using a Misonix S-4000 ultrasonic liquid processor, with a 419 microtip probe attachment
(Misonix, Inc., Farmingdale, NY).
Antiviral Assay
An assay originally developed for measuring HIV-1 mutation rate was modified
for high-throughput screening of nanoparticle antiviral activity (8). This assay uses an
HIV-1 vector system that measures a single cycle of viral replication through the point of
proviral gene expression. The HIV-1 particle carries the hygromycin-B resistance gene
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for selection and the envelope protein of Vesicular stomatitis virus (VSV), a species of
virus from the Rhabdoviridae family that enters cells by a pH-dependent fusion
mechanism mediated by the envelope protein. This viral pseudotype was produced by
transient transfection of three separate plasmids as previously described (8). Briefly, 3 μg
of the viral vector backbone ∆gag
(
-pol), 1 μg of the VSV-glycoprotein and 3 μg of the
helper plasmid containing gag-pol were transfected via Lipofectamine2000™
(Invitrogen, Carlsbad, CA) into 293T/17 cells (ATCC, Manassas, VA) following the
Invitrogen’s protocol. 293T/17 cells were plated at 2 x 105 cells in 60 mm2 dishes 24
hours prior to transfection. Forty-eight hours post transfection the supernatant containing
the infectious yet replication deficient viral vector, was harvested and used immediately
for infections.
Infections for the nanoparticle screen were modified from the previous study by
using a quantity of virus equal to or greater than 2.5 times the tissue culture infectious
dose 50% (TCID50) as determined by the Karber method (11). Infections were performed
in 96-well microtiter plates containing Vero76 cells (ATCC, Manassas, VA) at a density
of 1 x 104 cells per well, plated 24 hours prior to infection. Varying AgNP
concentrations, prepared in serum-free cell medium, were mixed 1:1 with fresh, not
previously frozen, virus stock for one hour at 37°C. After one hour, medium was
aspirated from each well and a 50 μL volume of the virus-AgNP mixture was applied to
the appropriate wells. The infection mixture was incubated at 37°C for one hour and
removed from the monolayer by aspiration. A final volume of 200 μL of medium was
added to each well. Twenty-four hours post-infection, a 200 μL volume of medium
containing 400 μg mL-1 hygromycin-B (Hyg) was added to each infected well and to the
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uninfected selective medium positive control wells. Negative control wells, containing
uninfected cells incubated with each AgNP concentration, were given 200 μL of normal,
non-selective medium. The medium was replaced in this manner every four days for two
weeks to allow for the selective effects of Hyg.
A cytotoxic assay was conducted after the two-week Hyg selection period to
quantify viral infection using the chemical MTT as the colorimetric reagent and 0.04 N
HCl in isopropanol as the stop solution (16). Trypsin was used as part of the protocol to
disrupt colonies and allow cell exposure to the MTT chemical. The optical density (OD)
was measured at 570 nm using a Dynatech Laboratories MRX automated plate reader
(Dynex, Richfield MN). A One-way ANOVA statistical analysis of the MTT results from
three independent experiments was performed using SigmaPlot 11.0 software comparing
each dose to the untreated control (Systat Software, Inc., San Jose, CA). P-values of less
than 0.050 were considered statistically significant. For each experiment, traditional
colony-forming unit (CFU) assays were performed in parallel as previously described to
quantify the viral titer and ensure sensitivity in the new assay (8). Briefly, the freshly
harvested virus was serially diluted 10-fold, from the undiluted stock down to a dilution
of 10-4, and each 10-fold dilution was used to infect Vero 76 cells, which were plated out
at 5 x 105 cells in 60 mm2 dishes 24 hours prior to infection. The infection took place for
one hour then infection dilutions were aspirated and replaced with non-selective medium
and incubated at 37°C overnight. After 24 hours the medium was changed to selective
media containing Hyg. The medium was aspirated and replaced every four days for two
weeks, at which time the plates were stained with a solution of 0.1 % Crystal violet in
100% ethanol.
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RESULTS
Nanoparticle Characterisitics
AgNPs were evaluated via TEM for size, morphology, and surface coatings (Fig.
1A). Multiple TEM images selected at random from separate preparations were analyzed
and over 200 particles were measured to confirm the AgNPs were generally spherical
with an average diameter of 25 nm ± 10 nm. Negative staining of AgNPs with uranyl
acetate demonstrated that the particles were completely surrounded by the heavy metal
stain, gradual darkening up to the perimeter of the nanoparticle, indicating that there were
no organic surface modifications such as surfactants or capping agents (Fig. 1B). If
organic surface modifications were present the gradual darkening surrounding each
nanoparticle would be interrupted by a relatively white-colored halo superficial to the
dark nanoparticles’ perimeter.

Figure 1. Transmission electron micrographs of AgNPs. A) Unstained AgNPs applied to Formvar coated
grid were analyzed for morphology and size, bar = 100 nm. B) AgNPs negatively stained with 3% uranyl
acetate to detect organic surface modifications, bar = 0.2 μm.
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Antiviral Assay Validation
Viral titers obtained from the new assay were compared to those obtained from
the traditional CFU assay in order to validate the new drug-screening platform. As can be
seen in Fig. 2, the OD readings from the new assay correlated well with the CFU output
of the traditional assay. Two representative fresh virus stocks harvested immediately after
the transfection period (one high and one low titer) were chosen for the comparison. The
titers of these virus stocks were 10-fold apart as measured by the traditional CFU assay (1
x 104 and 1 x 103 CFU mL-1 for the high and low titer stocks, respectively), which made
for a convenient comparison. In agreement with theoretical prediction, when the hightiter virus stock was diluted by 10-fold, it yielded a similar OD reading to that of the
undiluted low-titer stock, (compare open circle at dilution 10-1 with closed circle at
undiluted, Fig. 2). Similarly, when diluted by 100-fold, the high-titer stock gave a similar
OD reading to that of the 10-fold dilution of the low titer stock (compare open circle at
dilution 10-2 with closed circle at dilution 10-1, Fig. 2). The 100-fold dilution of the lowtiter stock reached the cut-off OD value of 0.3 for the MTT assay, i.e. it was out of the
linear range on the lower end (closed circle at dilution 10-2, Fig. 2), and did not follow the
same correlation trend. The new assay accurately detected changes in infectious virus
over 99 % of the total infectious viral titer generated. The uninfected cell control (closed
triangle at undiluted, Fig. 2) showed a similar OD as compared with the undiluted high
titer virus stock (open circle, Fig. 2), suggesting that both conditions had reached
confluence in their respective wells and attained the upper limit of the assay’s linear
range.

64

Figure 2. Correlation of viral titers obtained by optical density and colony forming unit readout. Fresh
virus stocks were measured in parallel using the new MTT-based assay versus the traditional CFU-based
assay.

Nanoparticle Antiviral Activity
The antiviral activity of individual AgNP preparations was measured using the
MTT-based assay with three independent, fresh virus stocks (n = 3, Fig. 3). A
cytotoxicity assay was performed simultaneously with the antiviral measurement in the
same microtiter plate wherein cells were incubated in a non-selective medium with the
same doses of AgNPs without the addition of virus (Fig. 3). The AgNPs exhibited
statistically significant antiviral activity at doses as low as 2 μg mL-1 (p = 0.005). The
minimum inhibitory concentration 50% (IC50) of AgNPs against the virus was 16 μg mL1

. No false OD readings produced by AgNP reduction of MTT were observed in control

experiments where MTT was incubated with various AgNP concentrations (data not
shown). Cytotoxicity was insignificant, as demonstrated by one-way ANOVA, at all
doses up through 250 μg mL-1(p =≥ 0.340 at 250 μg mL

-1

). Significant AgNP

cytotoxicity was observed beginning at 500 μg mL-1 (p = 0.020). The increasing variation
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associated with the higher concentrations of AgNPs was a consequence of cells reacting
differently to these AgNP concentrations between experiments. However, even at the
highest dose tested (1,000 μg mL-1, data not shown), toxicity against the cells did not
reach the lethal dose 50% (LD50). Thus, the therapeutic index for the AgNPs is greater
than 63 as calculated by dividing the LD50 by the IC50.

Figure 3. AgNP antiviral activity and cytotoxicity. The new MTT-based assay was used to assess antiviral
activity and cytotoxicity across a range of AgNP concentrations. Data are represented as percent of
infected, untreated controls. Asterisks above the symbols represent values that were statistically significant
compared to the untreated control, as measured by one-way ANOVA for either the antiviral measurements
or the cytotoxicity measurements separately (n = 3).
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DISCUSSION
Many different tetrazolium-based assays exist for determining cell viability based
on metabolic activity. The assay described here utilizes MTT, which has been shown to
have advantages over other cytotoxicity assays due to its decreased evaporation errors,
low variability, and high sensitivity in 14-day cultures (4, 9, 18, 20). Since MTT is
reduced in the cytoplasm instead of at the plasma membrane surface, the chances that
nanomaterials bound to the cell surface will interfere with the chemical reduction of the
salt or the uptake of other dyes, such as neutral red (1).
Another advantage of MTT-based screening methods for AgNPs and other
metallic nanomaterials is the lack of interference with surface plasmon resonances
(SPRs), an innate physical property of metal nanoparticles responsible for their
characteristic colors, which can interfere with the OD readings of other cytotoxicity
assays, typically performed in the 400-500 nm range. The OD reading of the MTT assay
is performed at a wavelength of 570 nm, well past the characteristic SPR absorbance of
AgNPs (~400 nm) and unaggregated AgNPs less than 30 nm should not demonstrate
significant absorbances via SPR at 570 nm (6, 13). This new antiviral assay would also
be adaptable for nanoparticles with SPRs around 570 nm as it would be easy to simply
utilize a relative of MTT, such as MTS, XTT or WST-1, which absorb at different
wavelengths. Dye-based cytoxicity assays, including MTT and its chemical relatives,
have been shown to be problematic for certain carbon-based nanoparticles, particularly
carbon nanotubes (2, 14, 25). However, a recent study showed that the MTT assay
performed well with a non-carbon, metallic nanomaterial (quantum dots) indicating that
tetrazolium based assays are a legitimate means for detecting cellular viability and thus
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antiviral activity of nanomaterials when coupled with this method (14). The multiple
media changes that occur over the course of the new assay further reduce the chance that
nanomaterials will interfere with the OD readings because unbound nanomaterials are
washed away. MTT has also been shown to be superior to lactate dehydogenase and
trypan blue exclusion assays for determining cell viability, and thus antiviral activity
when coupled with this new method (3).
MTT-based assays have been used for determining cytotoxicity, viral titers, and
antiviral activity through cytopathic effects (CPE) for over 20 years (19). In fact, the
National Cancer Institute lists an MTT-based assay as a standard method for
characterizing nanomaterial cytotoxicity (24). Utilizing this standard tetrazolium based
assay to detect antiviral activity, in addition to cytotoxicity, eliminates the possibility of
translating cytotoxic effects of the nanomaterial as antiviral activity during traditional
plaque forming unit (PFU) or CFU methods with replication competent viruses. To the
authors’ knowledge this assay is the first of its kind to replicate the traditional CFU assay,
or reduction/neutralization tests, in high-throughput, 96-well plate format for the
purposes of screening antiviral activity. The widespread use of the MTT platform, in
general, suggests that many laboratories have the required automation capabilities, tools,
and reagents to carry out the new assay described within this communication.
Multiple concentrations of AgNPs incubated with the virus were used to
determine their antiviral activity. Existing technology, such as the traditional CFU and
PFU assays, are labor intensive and as a result do not permit easy examination of various
doses. This new assay serves as a preliminary screen for antiviral activity as well as a
rudimentary indicator of a possible antiviral mechanism. If antiviral activity is detected
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these results will then warrant further examination for the mechanism of antiviral
activity, post-exposure efficacy, multiplicity of nanoparticles (MON) required to inhibit
infection, cytoprotective effects of the nanomaterial and the MON required for possible
cytoprotective effects.
A recent report suggests that inhibition of HIV-1 by AgNPs occurs at an early
stage of infection (12). The current assay supports this data by allowing for mechanistic
studies in the critical early stage of infection; later events in the viral replication cycle are
intentionally blocked through genetic engineering of the virus (8). Furthermore, CPE
normally associated with late-stage HIV-1 infection are eliminated, allowing for
proliferation to be measured. In this way, CPE of the virus is not mistaken for
nanoparticle cytotoxicity.
The viral pseudotyping system employed in the current study broadens the utility
of the new assay and provides standardization. Many different viral envelope proteins can
be placed on the outside of the HIV-1 particle to simulate infection for different viruses.
This interchangeable envelope protein is additionally advantageous through its ability to
simulate, at lower levels of biocontainment, viruses normally studied under
biocontainment levels 3 and 4. This pseudotyping adaptability ensures that varying levels
of CPE that might be associated with the parental viruses are not falsely interpreted as
enhanced or reduced antiviral activity against the simulated virions when comparing
prospective new agents.
CONCLUSIONS
A new high-throughput screening assay was successfully developed and used to
simultaneously measure the antiviral activity and cytotoxicity of nanomaterials in a cell
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culture-based system creating a new system by which nanomaterials can be screened for
antiviral activity. Furthermore, the results of this assay can serve as a “finger in the
wind,” from which the direction of future mechanistic studies of nanomaterial antiviral
activity. In the process of validating this new assay with a contemporary nanomaterial,
silver nanoparticles showed clear-cut antiviral effects and low cytotoxicity,
demonstrating a potential treatment with a high therapeutic index. The AgNPs inhibited
the virus at an early stage of replication prior to assembly of new particles in the cell.
Further investigation into the mechanism of nanoparticle antiviral activity is warranted.
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CHAPTER IV
Silver Nanoparticles Inhibit Vaccinia Virus Infection by Preventing Viral Entry

ABSTRACT
Nanotechnology, specifically silver nanoparticles (AgNPs), have gained
tremendous attention and increasing presence in consumer products for their
antimicrobial properties despite defined mechanisms of activity. Vaccinia virus (VACV),
is a common analog for the study of Variola major, a Category A pathogen and a high
priority for the development of effective antiviral agents. This study hypothesized that
AgNPs inhibit VACV infection by preventing viral entry. A VACV reporter assay,
designed specifically for the viral entry window, demonstrated that AgNPs significantly
prevent VACV entry at doses as low as 8 μg mL-1 with an IC50 value as low as 48 μg mL1

. Confocal microscopy confirmed the anti-entry effect of AgNPs, with significant

inhibition as low as 32 μg mL-1. AgNPs prevented both direct fusion and
macropinocytosis-dependent entry of VACV in a virucidal capacity. Western blot data
suggested that AgNPs may bind directly to the entry fusion complex of VACV at antientry concentrations revealing a potential virucidal mechanism. Inhibition of entry was
demonstrated at non-cytotoxic doses as determined by MTT and trypan-blue exclusion
assay. Observations were made for an additional mechanism of AgNP antiviral activity
based on the loss of AgNP anti-entry effects after knockdown of Pak1, a vital component
of macropinocytosis. Furthermore, plaque assays demonstrated AgNP inhibition of the
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entire VACV replication cycle. These data suggest that AgNPs could be a potent antiviral
therapeutic due to their multiple mechanisms of antiviral activity.
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INTRODUCTION
Nanotechnology, an emerging field of research for materials with one dimension
between 1 and 100 nm, is generating a significant presence among new commercially
available products with the general public recognizing it as a buzzword and the scientific
community presently hard at work discovering new applications. Metal nanoparticles,
particularly silver nanoparticles (AgNPs), have received tremendous attention recently
for their observed antimicrobial properties. Applications utilizing AgNPs have multiplied
over 1,000% since 2006 with AgNPs representing 313 of the 1317 licensed
nanotechnology products (55). Most of the commercial applications for AgNPs are
antimicrobial; for example, AgNPs are commercially available as preservatives (i.e.
clothing and cosmetics), medical devices (i.e. coatings for catheters and wound
dressings), and as water treatment agents with no defined mechanism for their
antimicrobial properties (11, 17, 39).
AgNP antimicrobial activity is a rapidly expanding new field of research and
development due to the benefits this technology can provide. For example, because they
are a metal, AgNPs are highly resilient to changes in temperature and humidity relative to
traditional antimicrobials. AgNPs also have an advantage over traditional antibiotics and
antivirals in their lack of microbial resistance. In addition to the benefits over traditional
antibacterial and antiviral agents, AgNPs have been observed to exert antimicrobial
effects on a wide range of bacteria and viruses, making AgNPs a true broad-spectrum
antimicrobial (32). Since an exponentially increasing number of products are approved
for public consumption each year, this study sought to understand the mechanisms behind
AgNP mediated antiviral activity, for which these products are marketed.
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AgNPs exhibit large surface to volume ratio and low coordination numbers that
result in enhanced catalytic and reactive abilities which lead to their antimicrobial activity
(5, 50). AgNPs bind to biological material non-specifically through their inherent
requirement for steric and electrostatic stabilization as a result of their highly polarized
surfaces and empty S1 orbital at the zero valent state (5, 30). Covalent bonds are thus
easily established, with complexes containing nitrogen (amines/protein), phosphorus
(phosphanes/DNA) and sulfur (thiols/protein) being common electron donors (5).
Various mechanisms for the antimicrobial properties of AgNPs have been
proposed (38, 40). However, these studies mostly examined the antibacterial properties of
AgNPs. Relatively little data is available for the mechanism of AgNP antiviral activity,
which could differ drastically due to the inherent differences between bacteria and
viruses. The antiviral activity of AgNPs has been documented in many different viral
species including the human pathogens HIV-1, HBV, MPV and TCRV (12, 21, 23, 34,
41). Each study suggested that an early event in viral infection is the likely point of
AgNP antiviral activity.
Variola major, an Orthopoxvirus and the causative agent of smallpox, is a
Category A pathogen and a growing concern as a potential biological weapon due to
decreased population immunity as a result of the cessation of vaccination. Study of
Variola major virus is restricted to only one location within the United States. However,
an accurate analog for the study of Variola major is available in the form of the virus
used as the vaccine for smallpox, Vaccinia virus (VACV). Due to the similarities with
Variola major and its use in vaccination, VACV has become the gold standard for
research on Orthopoxviruses. Multiple government agencies have listed the development
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therapeutics for Category A pathogens a high priority, which makes VACV an attractive
target for investigations into the antiviral activity of AgNPs (49).
VACV is a double stranded DNA virus of about 200kb and it replicates solely in
the host cell cytoplasm. The large genome encodes almost all of the structural proteins
and enzymes required to complete its replication process (9). There are two infectious
forms of VACV: the mature virion (MV) and the extracellular virion, which differ from
each other by the number of envelope membranes and a few proteins (33). This study will
focus on the MV form of VACV. The infection process begins with VACV adsorption to
the membrane of a permissible host cell. This binding to the cell surface is accomplished
through VACV membrane proteins A27 and H3, D8, L1 and A26, which bind heparan
sulphate, chondroitin sulphate, and laminin respectively (8, 13, 15, 22, 31, 52). At this
stage in the infection process the virion is bound to the cell surface but has not yet
entered the cell.
VACV demonstrates two methods of entry, which makes it an ideal candidate for
the investigation, because these methods can be independently assessed for a better
understanding of AgNP mediated anti-entry effects. Both entry methods are dependent on
a set of entry fusion complex proteins. Entry of VACV via the entry fusion complex
(EFC) has been demonstrated at both neutral and low pH (4, 37, 51). Identified as a
complex of proteins, the EFC is composed of A16, A21, A28, F9, G3, G9, H2, I2, J5, L1,
L5, and O3, with nine out of twelve of these proteins considered integral members of the
EFC as their disruption or removal destabilizes the complex (4, 6, 16, 27-29, 36, 44, 45,
48, 54). The stoichiometry of the complex and its precise mechanism of action have yet
to be classified or determined (53).
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Entry into the host cell is broadly characterized as the delivery of the virion core
to the cytoplasm. The viral core comes equipped with all the enzymes necessary to begin
early transcription (33). Once the viral core has entered the cytoplasm, it immediately
begins to transcribe early genes (7). This process has been documented to occur within
the first six hours of infection and is measurable via reporter assay with protein
expression driven by a constitutive early/late promoter (16, 52). One pathway for VACV
entry is acid-mediated and dependent on macropinocytosis (10, 43, 46). Additionally,
VACV adsorption induces the activation of mediators for macropinocytosis, such as the
serine-threonine kinase p21 activated kinase 1 (Pak1); without this cellular signaling
component there is little to no macropinocytotic uptake of VACV (25). The other mode
of VACV entry is direct fusion of the virion membrane with the plasma membrane (8, 31,
46). Both methods are dependent on the correct function of the EFC.
A mechanism through which viral infection is inhibited by AgNPs has yet to be
determined. This study investigates the hypothesis that AgNPs exert their antiviral
activity by preventing viral entry. VACV was chosen as the viral system to test this
hypothesis due to the increased concern of the use of its close relative Variola major in a
potential bioweapon and the call for the development of therapeutics for Category A
pathogens. Also, VACV demonstrates multiple methods of cellular entry, which can be
analyzed separately to gather a clear picture of how AgNPs mediate broad-spectrum
antiviral activity.
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MATERIALS AND METHODS
Antibodies, cell lines, nanoparticles and viruses.
The BS-C-1 (CCL-26), Vero 76 (CRL-1587) and HeLa (CCL-2) cell lines were
acquired form American Type Culture Collection (Manassas, VA) and grown according
to manufacturer recommendations. All infections were performed with VACV in the MV
form. Powdered AgNPs, certified 99.99% pure silver and average 25 nm in diameter,
were acquired from NovaCentrix Inc. (Austin, TX) and further characterized as
previously described (Chapter III, Figure 1). NovaCentrix particles were used for every
experiment unless otherwise noted. Prior to use, NovaCentrix AgNPs were suspended in
ultrapure water and sonicated for 30 seconds via Misonix S-4000 ultrasonic liquid
processor equipped with a 419 microtip probe (Misonix Inc., Farmingdale, NY). AgNPs
were then diluted, in complete growth medium, to their desired concentrations for each
assay. Tangential flow ultrafiltered AgNPs were prepared and characterized as previously
described and diluted in complete growth medium (47). Vaccinia immune globulin (NR2632) was acquired from BEI Rescourses (Manassas, VA). Rabbit-anti-Pak1 monoclonal
antibody (2602S) was acquired from Cell Signaling Technology (Beverly, VA) and used
according to manufacturer specifications. Rabbit-anti-β-actin monoclonal antibody
(#4970S) was acquired from Cell Signaling Technology and used as per manufacturer
instructions. Donkey-anti-rabbit polyclonal secondary antibody conjugated to horseradish
peroxidase was acquired from Thermo-Fisher-Pierce (#SA1200, Pittsburgh, PA) and used
according to manufacturer specifications. Rabbit-anti-G9 polyclonal antibody was
acquired from AbCam (#ab93828, Cambridge, UK) and used according to company
specifications. vSC56, a genetically engineered Western Reserve strain of VACV
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expressing β-galactosidase (β-gal) under the control of a constitutively active early/late
promoter in place of the TK gene, was a generous gift from Dr. Hanna Golding at The
Food and Drug Administration (24). WR-A4-GFP, a Western Reserve strain of VACV
genetically engineered with its A4 core protein fused to GFP, was a generous gift of Dr.
Bernard Moss at the National Institute for Allergy and Infectious Disease (3).
Viral stock preparation.
All viruses used in this study were propagated by infecting HeLa monolayers
grown to confluence in T-150 flasks (CLS430825-50EA, Sigma-Aldrich Corp., St. Louis,
MO). Monolayers were harvested after reaching >90 % cytopathic effects then detached
with sterile glass beads. The supernatant was then collected with the culture medium in
50 cc conical tubes and centrifuged for 5 minutes at 514 x g. The supernatant was
discarded and the cell pellet was resuspended in 5 mL of PBS and subjected to three
rounds of rapid freeze-thaw via dry ice/ethanol bath and 37°C water bath to free MVs
trapped within the cells and to disrupt the outer membrane of extracellular virions. Cell
debris was then cleared from the lysates by centrifugation for 5 minutes at 514 x g. The
supernatant was then collected and syringe filtered through a 0.45 μm filter. The viral
suspension was then aliqouted and stored at –70°C until use.
Viral titering.
All viral titering experiments were performed on the BS-C-1 cell line in 6-well
plates seeded at 5 x105 cells per well 24 hours prior to infection. On the day of infection
the virus to be titered was diluted in 10-fold serial dilutions in serum free medium and
500 μL of each dilution used to infect the monolayer for 2 hours. After two hours, the
infection mix was aspirated and the monolayers overlaid with 2 mL of 1.25 % SeaPlaque
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agarose (Lonza Rockland Inc., Rockland, MD) in complete growth medium. Once the
overlay solidified at room temperature the plates were incubated at 37°C for 2 days at
which time 200 μL of a 1.66 mg mL-1 solution of 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) was then dropped on top of the agarose overlay to
stain live cells purple and provide contrast for the identification of plaques. Plates were
then further incubated at 37°C for 4 hours to let the stain develop and then plaques were
counted.
Plaque assay for virion absorption.
Vero76 and BS-C-1 cells were plated at 5 x 105 cells per well in each well of a 6well plate 24 hours prior to the day of the assay. On the day of the experiment WR-A4GFP at 8.6 x 109 pfu mL-1 was serially diluted 10-fold and exposed to 0, 8, 32, and 128
μg mL-1 of AgNPs for 1 hour at 37°C. After one hour, Vero 76 cells and the AgNP/WRA4-GFP mixtures were then cooled to 4°C on ice for 30 minutes in order to prevent viral
entry. The chilled AgNP/WR-A4-GFP mixture was used to infect the Vero 76
monolayers on ice for 1 hour. After 1 hour, the monolayers were washed three times with
ice cold PBS and brought to a final volume of 2 mL PBS after washing. Vero 76
monolayers were then detached from the plate by scraping and collected in 50 cc conical
tubes. Cells were then lysed by rapid freeze-thaw three times in a dry ice/ethanol bath,
followed by 37°C water bath. After cells were lysed, the lysates were then serially diluted
10-fold and subjected to viral titering on the BS-C-1 cells plated 24 hours previously, as
described in the “viral titering” section.
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Confocal virion adsorption assay.
Vero 76 cells were plated at a density of 5 x 105 cells per well on glass cover slips
added to the bottom of 6-well plates 24 hours prior to infection. On the day of the
experiment WR-A4-GFP was diluted to a multiplicity of infection (MOI) of 1,000 in
complete growth medium containing 0, 8, 32, and 128 μg mL-1 of AgNPs and incubated
at 37°C for 1 hour. After 1 hour the AgNP/WR-A4-GFP mixture was then chilled to 4°C
along with the cells and culture medium for 30 mintues. Once the cells were chilled they
were infected with the AgNP/WR-A4-GFP mixtures on ice for 1 hour. After one hour,
the infection mixture was removed and the cover slips incubated with 5 μM CellTracker
Red CMPTX (Invitrogen, Carlsbad, CA) for 20 minutes on ice then aspirated and washed
with ice cold PBS prior to 30 minutes of fixation with ice cold 3.7% formaldehyde in
PBS. Cover slips were then mounted and examined as described in “Confocal entry assay
for fluorescent VACV.”
β-galactosidase entry assay.
The β-gal entry assay was based on a protocol developed by the FDA to measure
VACV neutralization after vaccination but modified to make it specific for detecting
VACV entry (24). All aspects of the β-gal entry assay were identical to those described
previously, except the following which made the assay specific for VACV entry (24):
Vero 76 cells were plated at 2.5 x 105 cells per well in a 12-well plate 24 hours prior to
initiating the assay. On the day of the assay, vSC56 was diluted to an MOI of 10 in
complete medium and incubated with various AgNP concentrations for 1 hour prior to
use for the virucidal condition. For the cytoprotective condition, cells were treated with
AgNP concentrations, at 2-fold incriments from 2 to 256 μg mL-1, for 1 hour then
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aspirated prior to infection with untreated vSC56. The AgNP/VACV mixture was then
added to the cells for the virucidal condition or untreated vSC56 was added to previously
AgNP treated cells for the cytoprotective condition. The infection was then carried out
for 4 hours, at which time each well was aspirated then trypsinized with 0.25% trypsin in
Hank’s Balanced Salt Solution. The trypsin was inactivated by the addition of an equal
volume of complete medium and the detached cell suspension was collected in a 1.5 mL
tube then centrifuged at 0.3 x g for 5 minutes. The supernatant was discarded and the cell
pellet was then lysed with 4 % IGEPAL CA-630 in complete growth medium for a period
of 1 hour at 37°C. Optical Densities collected at 570 nm on a Dynex MRXe Revelation
plate reader (Dynex Inc., Chantilly, VA) were then used to calculate the percent of
untreated control for each sample. For β-gal assays accompanied by a knockdown of
Pak1, cells were plated out at 2.5 x 105 cells per well two days prior to infection and
transfected with siRNA 24 hours prior to infection with vSC56.
β-galactosidase entry assay validation.
As described previously, β-gal standards were used to ensure that the assay was
operating within a measurable linear range and VIG was used as a positive control for
inhibition of vSC56 entry (24). Briefly, 7 standard concentrations of β-gal were serially
diluted from a 1,500 U mL-1 stock solution (#10105031001, Roche Diagnostics,
Indianapolis, IN) to 0.6, 1.2, 2.3, 4.7, 9.4, 18.6, and 37.5 mU mL-1 in 4:1 Z-buffer:PBS.
The series of β-gal standards was then incubated with AgNPs at 4, 8, 16, 32, 64, 128,
256, 512, and 1024 μg mL-1 for 1 hour at 37°C. After one hour 20 μL of a 4 mg mL-1
chlorophenol red β-D-galactopyranoside (CPRG) substrate (#10884308001, Roche
Diagnostics, Indianapolis, IN) in 0.1 M sodium phosphate (pH = 7.0) was added to each
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standard and incubated at room temperature for 30 minutes. At 30 minutes the OD at 570
nm was read as described in the previous section. The OD values were normalized to
AgNP only wells to account for any OD readings brought about by the AgNPs
themselves. The standard/AgNP OD values were then plotted against the β-gal
concentrations to generate an XY scatter plot from which a linear trend line could be
established. The linear trend line was then subjected to R2 analysis (Microsoft Excel
2003, Microsoft Inc., Redmond, WA). R2 values less than 0.99 were considered
unacceptable, as the standard enzyme did not catalyze the substrate properly. β-gal
standards were run in parallel for each β-gal assay to determine if the results were in the
linear range and acceptable. VIG was used as a positive control to determine if the assay
was capable of detecting vSC56 entry inhibition. The VIG was serially diluted 2-fold and
incubated with vSC56 at an MOI of 10 for 1 hour at 37°C. After the one-hour incubation
the infections with the VIG/vSC56 mixture were carried out and ODs collected as
detailed in the previous section.
Confocal microscopy entry assay with fluorescent VACV.
Vero 76 cells were plated onto glass cover slips in the bottom of 6-well plates 24
hours prior to infection at 5 x 105 cells per well. Fluorescent virus WR-A4-GFP was then
diluted to an MOI of 1,000 in complete medium containing various concentrations of
AgNPs and incubated for 1 hour at 37°C. The AgNP/WR-A4-GFP mixture was then
added to cells after the 1-hour incubation for the virucidal condition. For the
cytoprotective condition, cells were incubated with various concentrations of AgNPs in
complete medium for 1 hour prior to aspiration and addition of untreated WR-A4-GFP at
an MOI of 1,000 in complete growth medium. Infections for both the virucidal and
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cytoprotective conditions were carried out for 1 hour at 37°C when each well was
aspirated. A solution of 1 μM CellTracker Red CMPTX (C34552, Invitrogen, Carlsbad,
CA) in serum free medium was then added to each well and incubated at 37°C for 20
minutes. After 20 minutes the CellTracker solution was removed via aspiration and the
cover slips were washed with PBS twice. The cover slips were then fixed with 3.7%
formaldehyde in PBS for 30 minutes. Cover slips were then removed from their
respective wells and mounted on glass microscope slides for viewing on an Olympus FV300 confocal microscope equipped with both 488 and 568 nm argon and krypton laser
excitation lines, respectively. Scans were acquired every 0.4 μm starting below the
monolayer and proceeding past the top of the monolayer to encompass each cell in the
viewing area. Green and red channels were acquired separately then merged via Fluoview
5.0 software. Each z-stack was then analyzed frame by frame with Image-Pro 6.2
software (Media Cybernetics, Inc., Bethesda, MD) to manually tag each green core
within the cytoplasm, stained red by CellTracker Red CMPTX. A total of n = 3
experiments were conducted for each condition and for each experiment a minimum of
150 cells were counted for each condition. Core counts were normalized to the number of
cells per condition per experiment. Percentages of untreated controls were then calculated
for each experiment and averaged together. For confocal entry assays involving the
knockdown of Pak1, cells were plated 48 hours prior to infection. At 24 hours prior to
infection the cells were transfected with siRNA specific for Pak1.
Pak1 knockdown via siRNA.
The knockdown of Pak1 was accomplished by transfecting 50 pmol of each of
three separate 27-mer siRNAs with Lipofectamine 2000 (Invitrogren) per 5 x105 cells, 24
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hours prior to use in experiments, according to manufacturers protocols. The siRNA was
designed to target regions of high homology for Pak1 between Homo sapiens (NCBI
Gene ID # 5058), Mus musculus (NCBI Gene ID # 18479, Macaca mulatta (NCBI Gene
ID # 698585) and Callithrix jacchus (NCBI Gene ID # 100392970). The target sequence
of siRNA1 is UUAGCUUGACAGAGCCAUCCAUUCCCA. The target sequence of
siRNA2 is AGUCUCAGACACAGCCUUCACAUUCAA. The target sequence of
siRNA3 is AUUAUAAUCCUCAGCUGACUUAUCUGU. All siRNAs were synthesized
by Integrated DNA Technologies (IDT, Coralville, IA).
Western blotting.
Cellular lysates were created by pelleting cells at 0.3 x g after trypsinization then
adding lysis buffer containing phoshatase inhibitors (50 mM Tris-HCl pH 8, 120 mM
NaCl, 5 mM NaPPi, 10 mM NaF, 30 mM paranitrophenylphosphate, 1 mM benzamidine,
0.1%NP-40, 1% Triton X-100, and 0.2 mM PMSF, 100 nM sodium orthovanadate)
supplemented with protease inhibitors. A BCA protein content analysis kit was then used
to determine the protein content of the lysates (#23221, Thermo-Fisher-Peirce,
Pittsburgh, PA). Fifty micrograms of protein were then diluted and boiled for 10 minutes
with a loading dye containing 0.5M dithiothreitol, 10% sodium dodecyl sulfate, 0.5M
Tris (pH 6.8), 50% glycerol and 0.2% bromophenol blue. Lysates were then resolved on a
10 % SDS-PAGE gel (C = 3.3%) and then transferred to a polyvinylidene fluoride
membrane (PVDF). The PVDF membrane was then probed with primary antibody
specific for Pak1, β-actin, G9 or GFP according to manufacturer specifications.
Secondary antibody conjugated to horseradish peroxidase were then added according to
manufacturer protocol then detected via Supersignal Westpico Chemiluminescent
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Substrate kit (Thermo-Fisher-Pierce, Pittsburg, PA). Chemiluminesense was detected
using a Fuji LAS-4000 gel documentation center (Fujifilm, Tokyo, Japan). Densiometry
readings were measured via Multiguage software (Fujifilm). For the western blot
analyzing mobility shift in G9 and A4-GFP, AgNPs were added directly to WR-A4-GFP
stocks at 0, 10, 100, or 1,000 ug mL-1, then incubated for 1 hour at 37°C for one hour.
After one hour, virus was lysed by adding 2x radio-immuno-precipitation-assay (RIPA)
buffer to an equal volume of virus/AgNP mixture and the whole lystae was then resolved
by SDS-PAGE and immunoblot analysis, as described above. The 2x RIPA buffer
contained 300 mM sodium chloride, 2% IGEPAL CA-630, 1% sodium deoxycholate,
0.2% SDS and 100 mM Tris, pH = 8.0.
Plaque reduction assays.
Plaque reduction assays were conducted using WR-A4-GFP tittered at 8.6 x109
pfu mL-1 as the untreated control. For the cytoprotective condition of the plaque reduction
assays, cells were incubated with various concentrations of AgNPs (one concentration per
experiment) for 1 hour at 37°C prior to infection with 10-fold serial dilutions of untreated
virus in complete growth medium. Virucidal plaque reduction assays were conducted by
incubating the 10-fold serial dilutions of WR-A4-GFP with concentrations of AgNPs at
32 μg mL-1 for one hour at 37°C prior to infecting BS-C-1 monolayers. This
concentration of AgNPs was used for the plaque assays as it demonstrated significant
inhibition of viral entry during the β-gal for overall VACV entry. After the hour
incubation of the cells with AgNPs for the cytoprotective condition or the virus with
AgNPs for the virucidal condition infections were performed in a procedure identical to
that detailed in the “Viral titering” section. For post-infection plaque reduction assays
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infections were carried out as described in the “Viral titering” section with the addition of
AgNPs at 32 μg mL-1 to the 1.25 % SeaPlaque agarose overlay.
Cytotoxicity of AgNPs.
Vero 76 cells were plated at 2.5 x105 cells per well in 96-well plates 24 hours
prior to treatment with AgNPs. On the day of each experiment AgNPs were diluted in
complete growth medium and added to corresponding wells of the plate for 1, 4, 24 and
48 hours. At the end of each time point the wells of the plate were aspirated and washed 3
times with PBS then 100 μL of complete growth medium was again added to each plate
along with 30 μL of a 1.66 mg mL-1 solution of MTT. The plate was then incubated for 4
hours at 37°C. At the end of the 4 hours, cells and MTT were solubilized with 0.04 N
HCl in 2-propanol at which point the OD at 570 nm was then read on a Dynex MRXe
plate reader. Control conditions containing AgNPs and cells with no MTT were used to
normalize the OD results for each AgNP condition and thus account for any OD reading
from the AgNPs themselves.
Statistical analysis, plots and IC50/LD50 Calculations.
SigmaPlot 11.0 software (Systat & Mystat Products, Chicago, IL) was used to
create graphs and conduct One-way ANOVA statistical alalyses. Percent of control
values for test conditions were compared to the 100 % untreated control groups. P-values
of less than 0.05 were considered statistically significant. Inhibitory concentration 50%
(IC50) and lethal dose 50% (LD50) values were calculated according to the Karber Method
with a positive or negative reaction boundary at 50 % of the untreated control (18).
Adobe Photoshop was used to crop and size graphics (Adobe Systems Inc., San Jose,
CA).
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RESULTS
Effect of AgNPs on adsorption of VACV to host cells.
In order to determine the point at which AgNPs inhibit VACV infection,
adsorption of VACV was first investigated. The plaque assay used to measure adsorption
of VACV relies on infecting cells at non-entry conditions, washing out unbound virions
and then lysing cells to recover infectious virus that had adsorbed. AgNPs at 2, 8, 32, and
128 μg mL-1 exhibited the same titer as the untreated condition, 0 μg mL-1 (Figure 1A).
The slight increase in viral titers observed from VACV treated with 128 μg mL-1 was not
statistically significant by One-way ANOVA analysis. The results of the plaque assay
suggest that AgNPs at all concentrations tested had no effect on the adsorption of VACV
to host cells. Confocal microscopy using a Western Reserve strain of VACV expressing
GFP fused to the core protein A4 was then used to corroborate the findings of the plaque
assay (Figure 1B). The confocal assay demonstrated that AgNPs at concentrations of 8,
32, and 128 μg mL-1 had measurements within the range of the untreated control. Each of
the concentrations tested was not statistically significant from the untreated control, as
determined by One-way ANOVA. These results suggest that AgNPs had no affect on
VACV’s ability to adsorb to the host cell.
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Figure 1. Effect of AgNPs on adsorption of VACV to host cells. A) Viral titers obtained from WR-A4GFP treated with various concentrations of AgNPs then allowed to adsorb to host cells under non-entry
permissive conditions. B) Confocal microscopy quantification of WR-A4-GFP bound to host cells under
non-entry permissive conditions after treatment with various AgNP concentrations. Each AgNP
concentration is compared to the untreated control.
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Effects of AgNPs on overall VACV entry.
After adsorption, entry/fusion with the host cell is the next step in the VACV
infection cycle. To monitor the effect of AgNPs on this stage of VACV infection, an
assay measuring entry/fusion was developed utilizing VACV expressing β-gal under the
control of a constitutively active promoter. Since the proposed assay utilized β-gal, the
effect of AgNPs on the enzyme’s ability to catalyze its substrate was investigated. The R2
values obtained from every AgNP treatment condition, from 2 through 1024 ug mL-1,
were above the acceptability threshold of the assay indicating that the β-galactosidase
enzyme activity is not altered by the presence of AgNPs (R2 > 0.99, data not shown).
To further validate the β-gal assay as capable of measuring VACV entry at 4
hours post-infection, a known inhibitor of entry, VIG, was used as a positive control. A
clear dose dependent decrease in β-gal expression was found, with statistically significant
inhibition starting at 48 μg mL-1, as determined by One-way ANOVA (p = 0.032, Figure
2). Uninfected cells were used as a negative control and demonstrated OD values outside
of the linear range of the assay indicating that the target cell line does not endogenously
express β-gal (data not shown).
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Figure 2. Validation of β-galactosidase VACV entry assay. β-galactosidase expression quantifying
vSC56 entry in the presence of a known entry inhibitor, VIG. Each VIG concentration is compared to the
untreated control. Asterisks above a data point indicate statistical significance, as compared to untreated
control, according to One-way ANOVA (p ≤ 0.05, n = 3).
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Figure 3. Effects of AgNPs on overall VACV entry. Asterisks above a data point indicate statistical
significance, as compared to untreated control for each treatment condition, according to One-way
ANOVA (p ≤ 0.05, n = 3 for all experiments).

A) β-galactosidase expression from vSC56 quantifying

overall viral entry in the presence of various NovaCentrix AgNP concentrations. The cytoprotective group
represents cells incubated for 1 hour with AgNPs prior to infection with untreated vSC56. The virucidal
group represents vSC56 treated with AgNPs for 1 hour prior to use in infection. Each AgNP condition is
compared to the untreated control. B) Confocal microscopy quantification of WR-A4-GFP entry in the
presence of various AgNP concentrations. The cytoprotective group represents cells incubated for 1 hour
with AgNPs prior to infection with untreated vSC56. The virucidal group represents vSC56 treated with
AgNPs for 1 hour prior to use in infection. Each AgNP condition is compared to the untreated control.
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Figure 4. Tangential flow ultrafiltered AgNP virucidal effects on VACV entry. Asterisks above a data
point indicate statistical significance, as compared to the untreated control, according to One-way ANOVA
(p ≤ 0.05, n = 3). β-galactosidase expression from vSC56 quantifying overall viral entry in the presence of
various filtered AgNP concentrations.

Having established that VACV entry, and inhibition of this process, could be
reliably detected, AgNPs were then evaluated for their potential virucidal and
cytoprotective effects on overall VACV entry, both direct fusion and macropinocytosisdependent fusion. The cytoprotective condition, in which cells were incubated with
AgNPs prior to infection with untreated virus, demonstrated statistically significant
inhibition of viral entry, as determined by One-way ANOVA, starting at 8 μg mL-1, p =
0.020, with a break in statistical significance at 16 μg mL-1, p = 0.107. Statistically
significant inhibition resumed at 32 μg mL-1(p <0.001), and continued through the
highest dose examined, 256 μg mL-1 (Figure 3A). Additionally, the cytoprotective
condition exhibited a dose dependent decrease in VACV entry through the highest dose
examined with an IC50 of 90.66 μg mL-1. The virucidal condition, in which VACV was
treated with AgNPs prior to infection, exhibited statistically significant inhibition of
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VACV entry, as determined by One-way ANOVA, starting at 32 μg mL-1, p = 0.003, and
continuing through the highest dose tested, 256 μg mL-1. A dose dependent decrease in
viral entry was also observed for the virucidal condition with a sharp drop in viral entry
occurring above 32 μg mL-1. The IC50 value for the virucidal condition was 48 μg mL-1.
Confocal microscopy was used to corroborate the findings of the β-gal entry assay
using WR-A4-GFP. The cytoprotective condition exhibited a dose dependent decrease in
VACV entry with statistically significant inhibition at 128 μg mL-1, p < 0.001 (Figure
3B). The IC50 for the cytoprotective condition was 88 μg mL-1. The virucidal condition
exhibited statistically significant and dose dependent inhibition of VACV entry starting at
32 μg mL-1, with p = 0.010, and p = 0.001 for 32, and 128 μg mL-1 respectively (Figure
3B). The IC50 value for the virucidal condition was 88 μg mL-1. Together, these data
indicate that the β-gal entry assay can measure VACV entry and that AgNPs inhibit
overall VACV entry at low, therapeutic level concentrations.
Tangential flow ultrafiltered AgNPs were also used in the β-gal entry assay in a
virucidal capacity (Figure 4). Much like the NovaCentrix AgNP examined in Figure 3,
the filtered AgNPs exhibited a dose depended decrease in β-gal expression correlating to
a decrease in vial entry. Statistically significant inhibition of VACV entry, as determined
by One-way ANOVA, started at 16 μg mL-1 and continued through the highest dose
tested (p = 0.015, n = 3). The IC50 value from the filtered AgNPs was 128 μg mL-1. The
observation that two entirely different sets of AgNPs mediate an antiviral effects by
preventing VACV entry suggests that AgNPs, in general, exert their antiviral effects at
the entry stage of VACV infection.

97

Effects of AgNPs on the direct fusion entry pathway of VACV after Pak1
knockdown.
In order to determine if the effect of AgNP inhibition of viral entry was specific to
the direct fusion or macropinocytotic entry pathway of VACV, Pak1, a critical mediator
of macropinocytosis by functioning as a key signaling kinase to affect cytoskeleton
rearrangement, was knocked down via siRNA (25). Figure 5A demonstrates the efficacy
of each siRNA, individually and all together, to knockdown Pak1 expression. After
normalization to β-actin, siRNA#1, siRNA#2, and siRNA#3 demonstrated a 9, 54, and
81% knockdown of Pak1, respectively. However, all three siRNAs together (All, Figure
5A) were capable of generating an 87% knockdown of Pak1 expression compared to the
non-silencing control. A qualitative analysis through the uptake of a fluorescently labeled
dextran was also performed and demonstrated that all three siRNAs together reduced
fluid phase uptake among target cells (Supplemental Figure 1).
By knocking down Pak1 and subsequently reducing macropinocytosis in target
cells the macropinocytosis-dependent entry of VACV would be largely reduced. In
conjunction with Pak1 knockdown the ability of AgNPs to inhibit the direct fusion entry
pathway of VACV was then examined with the β-gal entry assay. Knockdown of Pak1
significantly inhibited VACV virus entry as β-gal expression values averaged only ~60%
of the non-silencing control (data not shown). The cytoprotective condition exhibited
very little ability to inhibit the direct fusion entry pathway of VACV with no statistically
significant inhibition of viral entry revealed after One-way ANOVA analysis.
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Figure 5. Effect of AgNPs on the direct fusion entry pathway of VACV after Pak1 knockdown.
Asterisks above a data point indicate statistical significance, as compared to the untreated control for each
condition, according to One-way ANOVA (p ≤ 0.05, n = 3 for all experiments). A) Western blot
quantification of Pak1 knockdown via siRNA. NSC = non-silencing control; All = all three siRNAs
together. B) β-galactosidase expression from vSC56 quantifying VACV entry after Pak1 knockdown in the
presence of various AgNP concentrations. Each AgNP concentration is compared to the silenced, untreated
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control on the y-axis. One-way ANOVA analysis for statistical significance was performed on each AgNP
treatment group compared to the silenced, untreated control. C) Confocal microscopy quantification of
WR-A4-GFP entry after Pak1 knockdown in the presence of various AgNP concentrations. Each AgNP
concentration is compared to the silenced, untreated control. A One-way ANOVA was performed on each
AgNP treatment group compared to the silenced, untreated control.

No IC50 value was obtained for the cytoprotective condition. The virucidal condition
exhibited a decrease in VACV direct fusion entry; however, the AgNP effect on direct
fusion of VACV was less potent than that found during examination of overall VACV
entry. Statistically significant inhibition of VACV direct fusion was only observed at 256
μg mL-1, p = 0.001 (Figure 5B). The visible decreases in viral entry observed at 64, 128
and 256 μg mL-1 corresponded to 23, 26, and 57% reductions in direct VACV entry
compared to the Pak1 silenced, untreated control. No IC50 value was reached for the
virucidal condition. These data indicate that AgNP anti-entry activity may largely require
host cell functions dependent on Pak1 activity, such as macropinocytosis. However, a
slight dose dependent decrease in viral entry was still observed for VACV treated with
AgNPs prior to infection suggesting that AgNPs might prevent direct fusion in a virucidal
fashion.
Confocal microscopy was again used to corroborate the results of the β-gal entry
assay. Silencing Pak1 demonstrated a significant effect on the number of WR-A4-GFP
cores found in the cytoplasm, with an average of ~60% of the non-silencing control (data
not shown). The cytoprotective and virucidal conditions exhibited no statistically
significant inhibition of the direct fusion entry pathway for VACV at any of the doses
examined (Figure 5C).. No IC50 values were reached for either condition. These confocal
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data obtained during the knockdown of macropinocytosis-dependent entry demonstrate
that AgNPs may require the function of Pak1, and possibly macropinocytosis, for
effective inhibition of VACV entry.
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Supplemental Figure 1. Fluid Phase Uptake Before and After Pak1 Knockdown. Vero 76 cells were
plated at a density of 5 x105 cells per glass cover slip and transfected at 24 hours with three siRNAs
targeting Pak1 as outlined in the methods section. At 24 hours post-transfection cells were infected with
WR-A4-GFP as described in the methods section, then pulsed for 10 minutes with a 1 mg mL-1 solution of
Rhodamine B-isothiocyanate (RITC) labeled 10,000 molecular weight dextran (#R8881, Sigma-Aldrich,
St. Louis, MO). Cells were then washed three times with PBS then fixed for 30 minutes in 3.7%
formaldehyde in PBS. Confocal images were then acquired, under identical exposure conditions, as
described in the methods section. Both images above are examples of one slice taken through the middle of
the z-stack acquired during analysis. Arrow indicates fluid phase uptake of the RITC-labeled dextran along
with WR-A4-GFP.
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Effects of AgNPs on the entire replication cycle of VACV.
To determine if the inhibition of VACV by AgNPs translated to global decreases
in VACV replication, a plaque reduction assay was performed. An AgNP dose of 32 μg
mL-1 was chosen to perform these plaque assays because this dose demonstrated
significant antiviral activity in the overall entry β-gal assay (Figure 3). Untreated VACV
generated an average control titer of 8.6 x 109 pfu mL-1 (Figure 6, Untreated, n = 2). The
virucidal condition, representing virus treated with 32 μg mL-1 for one hour prior to use
in infection, demonstrated a titer of 1.5 x 106 pfu mL-1, a 3.8-log reduction in viral titer
when compared to the untreated control (Figure 6, Virucidal, n = 2). The cytoprotective
condition, representing cells treated with 32 μg mL-1 for one hour prior to infection with
untreated virus, generated a titer of 6.6 x 105 pfu mL-1, a 4.1-log reduction in viral titer
when compared to the untreated control (Figure 6, Cytoprotective, n = 2). The postinfection condition, representing untreated cells infected with untreated virus and then
treated with 32 μg mL-1 AgNPs, exhibited a titer of 1.5 x 105 pfu mL-1, a 4.8-log
reduction in titer compared to the untreated control (Figure 6, Post-Infection, n = 2). The
virucidal, cytoprotective, and post-infection treatments of 32 μg mL-1 AgNPs
demonstrated statistically significant differences from the untreated control as determined
by One-way ANOVA, p = 0.009, p = 0.009, and 0.012 respectively. Additionally, a 2-log
reduction in viral titer was observed at both 8 and 16 μg mL-1 of virucidal treatment with
AgNPs (data not shown, n = 1 for both). The inhibition of the entire VACV replication
cycle suggests that AgNP inhibition of VACV entry has profound effects on viral
replication kinetics whether AgNPs are administered in cytoprotective, virucidal, or post
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infection fashion. Such drastic inhibition of viral replication could also be the result of an
as yet unknown mechanism(s).

Figure 6. Effects of AgNPs on the entire replication cycle of VACV. The Untreated group represents
VACV receiving no AgNP treatement. The Virucidal group represents VACV treated with 32 μg mL-1
AgNPs for 1 hour prior to infection. The Cytoprotective group represents cells treated with 32 μg mL-1
AgNPs for 1 hour prior to infection. The Post-Infection group represents untreated cells infected with
untreated VACV then overlaid with a 1.25 % agarose growth medium containing 32 μg mL-1 of AgNPs.
Asterisks above a data point represent statistical significance, as compared to the untreated control,
according to One-way Anova (p ≤ 0.05, n = 2 for all).
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AgNPs bind to the entry fusion complex of VACV.
Western blot was used to investigate the potential of AgNPs to bind to the EFC of
VACV to establish a possible mechanism of AgNP-mediated antiviral activity. A
reproducible (n = 2), dose dependent decrease in the mobility of EFC complex protein G9
was observed upon treatment of whole VACV virions with AgNPs (Figure 7, top panel).
Treatment of the virus at 100 and 1,000 μg mL-1 of AgNPs retarded the mobility of G9
equally, with 10 μg mL-1 showing retardation between that of the untreated control and
the bands at 100 and 1,000 μg mL-1. The untreated control showed a typical migration
pattern of a ~39 kD protein, G9 = 38.7 kD. Since the WR-A4-GFP virus was used for
these experiments, it was then possible to examine the migration of A4-GFP on the same
blot to determine if AgNPs were capable of penetrating the viral membrane and binding
the core fraction of the virus (Figure 7, bottom panel). The majority of the A4-GFP
protein showed no mobility shift as indicated by the thicker bands in the lower panel of
Figure 7; however, the 100 and 1,000 μg mL-1 AgNP treatment conditions had a small
portion of the total A4-GFP protein demonstrating a mobility shift .The shift in A4-GFP
was dose dependent with decreased mobility associated with increased AgNP dose. It is
possible that the process of lysing the virions gave excess AgNPs in the solution a chance
to bind the core proteins as well. These results suggest AgNPs are capable of binding to
viral proteins. Since G9 is an integral member of VACV’s EFC this binding may hinder
function of the EFC, generating a possible mechanism for virucidal AgNP-mediated antientry effects.
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Figure 7. AgNPs bind to the entry fusion complex of VACV. WR-A4-GFP was treated with 0, 10, 100
or 1,000 μg mL-1 AgNPs (indicated above the blots) and then subjected to western blot with antibodies
specific for the G9 protein, a member of the EFC, or GFP to detect mobility shifts in the respective
proteins.

Cytotoxicity of AgNPs.
In order to determine if the inhibition of viral entry was a function of AgNP
cytotoxicity and to gauge the therapeutic index of AgNPs, a standard MTT
metabolic/cytotoxicity assay was performed. At one hour of AgNP exposure, mimicking
the cytoprotective condition of the β-gal assays and all the confocal data, no statistically
significant cytotoxic effects were detected as determined by One-way ANOVA
comparing each dose to the untreated control (Figure 8, 1 hr). No LD50 was reached at 1
hour of AgNP exposure. At 4 hours of AgNP exposure, mimicking the virucidal
condition of the β-gal assays, there was a dose dependent decrease in the metabolic
function of the target cells starting at 32 μg mL-1 and continuing through the highest dose
tested (Figure 8, 4 hr). Statistically significant metabolic decreases, attained through Oneway ANOVA comparing each dose to the untreated control, were observed above 64 ug
mL-1, p < 0.001. However, the widely used trypan blue assay for detecting membrane
integrity, demonstrated that at 4 hours of AgNP exposure cell membranes were intact
excluding the dye. No differences in cellular morphology were detected at this
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magnification for all AgNP concentrations tested in the MTT assay. These data indicate
that at 4 hours of AgNP exposure the cells were intact but impaired metabolically
(Supplemental Figure 2, dead cells associated with dye uptake indicated with arrows). At
24 hours of AgNP exposure there was no statistically significant cytotoxicity, as
determined by One-way ANOVA comparing each dose to the untreated control,
indicating that the decreased metabolic function observed at 4 hours was a temporary
state and that the cells recovered (Figure 8, 24 hr).. A One-way ANOVA analysis of
MTT results from cells exposed to AgNPs for 48 hours exhibited no statistically
significant decrease in metabolic function when compared to the untreated control
(Figure 8, 48 hr). These findings show that AgNPs exert their antiviral, anti-entry effects
at non-cytotoxic concentrations and that there may be additional mechanism(s) for AgNP
antiviral activity involving a decreased metabolic state around 4 hours of AgNP
exposure.
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Figure 8. Cytotoxicity of AgNPs. MTT cytotoxicity data collected after 1, 4, 24 and 48 hours of exposure
to various AgNP concentrations (time points indicated in the bottom left hand corner of each graph). The
percent of control on the y-axis refers to the untreated control at each time point. Asterisks above a data
point indicate statistical significance, as compared to the untreated control for each time point, according to
One-way ANOVA (p ≤ 0.05, n = 3).

108

Supplemental Figure 2. Trypan Blue Exclusion Cytotoxicity Assay. Vero 76 cells were plated out at 2.5
x 105 cells per well in a 96-well plate 24 hours prior to exposure to AgNPs. Cells were then exposed to
AgNPs, at the doses listed in the top left corner of each panel, for 4 hours. Cells were washed once with
PBS then 80 μL of growth medium and 20 μL of trypan blue 0.4% were added to each well. Pictures were
taken on a Leica Ctr-6000 inverted microscope with the aide of Image Pro 6.2 software. Bar = 100 μm for
all panels. Arrows indicate dead cells no longer excluding the trypan blue dye.
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DISCUSSION
AgNPs have been observed to inhibit the viral replication cycle; however, while
the literature suggests an early time point in the viral replication process, little more is
known. This study identifies a distinct step in the viral replication cycle at which AgNPs
exert their antiviral effects. First, adsorption of VACV to host cells, the earliest in early
VACV replication processes, was examined to determine if this step of infection was
indeed the one interrupted by AgNPs to yield antiviral activity. No significant changes in
VACV adsorption were found among any of the AgNPs concentrations tested suggesting
that AgNPs do not interfere with the either the cellular proteins or VACV proteins
responsible for binding to host cells (Figure 1). It could be that the large branched
structure of the cellular factors heparan sulphate, chondroitin sulphate and laminin or
their viral binding counterparts A26 A27, D8, H3, and L1 are unperturbed by the binding
of AgNPs because this interaction is not dependent on a conformational change but rather
an electrostatic interaction (15). The binding of AgNPs may not abolish this charge
interaction or the AgNPs are capable of mimicking the charges responsible for normal
virus/host interaction via their highly polarizable surfaces, thus re-establishing any
abolished binding activity.
After determining that AgNPs did not affect adsorption, an assay was successfully
established to measure overall VACV entry, both direct fusion and macropinocytosisdependent fusion (Figure 2). This assay, based on the expression of β-gal driven from a
constitutively active early/late promoter, demonstrated that the reporter enzyme was
unaffected by the concentrations of AgNPs used in this study. Additionally, this assay
was capable measuring decreased VACV in conjunction with a known VACV entry
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inhibitor, VIG (Figure 2). These data demonstrated that VACV entry, or cores
translocated into the cytoplasm which immediately begin to transcribe early viral mRNA
resulting in early gene expression, can be accurately measured during a 4 hour, postinfection entry window. Successful reporter-based assays for VACV entry have detailed
the measurement of entry as late as 6 hours post infection further suggesting that reporter
assay detailed here, at 4 hours, is well within the generally accepted time frame of VACV
entry (16, 52).
AgNPs were found to significantly inhibit the entry process of VACV during βgal entry assay at 4 hours and confocal microscopic investigation at 1 hour post-infection
(Figure 3). The NovaCentrix AgNPs, a “top-down,” dry synthesis AgNP, had both a
cytoprotective and virucidal effect on VACV measured by decreases in viral entry in both
assays. Another set of AgNPs made via “bottom-up,” wet synthesis methods also
demonstrated clear dose dependent virucidal effects on VACV entry (Figure 4). These
findings agree with the literature suggesting that AgNPs exert antiviral steps at an early
stage of viral infection and add to it by pinpointing the stage of viral infection, the
entry/fusion process, at which AgNP antiviral activity occurs (12, 21, 23, 34, 41). These
findings also suggest that inhibition of VACV by AgNPs may not be as dependent on
AgNP size as HIV-1 has demonstrated (12). This size dependence was the result of the
HIV-1 entry protein gp120 being spaced at predictable intervals on the virus. The lack of
size dependence for VACV might indicate that the EFC responsible for VACV entry may
not have such a regimented spacing on the outside of the virion or that the virion is
simply too large for the ~11 nm filtered AgNPs and 25 nm NovaCentrix AgNPs to
sterically hinder themselves when binding to viral entry proteins.
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Since VACV is known to enter cells via two distinct mechanisms, direct fusion
and

macropinocytosis-dependent

fusion,

Pak1

siRNA

was

used

to

inhibit

macropinocytosis and permit investigation of the AgNP effect on the direct fusion entry
pathway of VACV (Figure 5). Pak1 was successfully knocked down to levels similar to
those found previously in the literature to inhibit macropinocytosis (Supplemental Figure
1) (25). Under these conditions, cytoprotective treatment with AgNP had almost no effect
on VACV entry. These results might be explained by the AgNPs being too spaced out on
the cell, at the lower concentrations, to bind to VACV or that they were exhausted by
binding to cellular proteins before a chance interaction with VACV. Effective AgNP
cytoprotective treatment of cells might indeed require macropinocytosis to bring AgNPs
and VACV into closer proximity in order to facilitate an inhibition of entry as AgNP
uptake into cells is macropinocytosis-dependent (2, 14). For example, in the tubular
domains of an endosome, which are between 50-90 nm in diameter, a 25 nm particle,
such as those used in this study, could occupy up to half of the luminal space (26). In the
vacuolar lumen of a macropinosome, which is between 200-1,000 nm in diameter, a 25
nm AgNP would occupy 2.5-12.5% of that diameter while a VACV virion, between 250350 nm, would occupy 25-35% of the that diameter (9, 26). While these values are
considering only two dimensions, the reduction in volume of the macropinosome as it
matures would increase the likelihood of VACV encountering an AgNP (9, 26). After
such an encounter with an AgNP and subsequent inhibition of fusion, the virus could
become trapped within the endosome and destroyed in the lysosome (19). AgNPs used in
a virucidal capacity were able to exert anti-entry effects on VACV’s direct fusion
mechanism but at much larger doses than those observed during the overall entry assays.

112

The increasing doses required to inhibit entry may be a result of the incomplete inhibition
of macropinocytosis and the excess AgNPs in the AgNP/VACV mixture creating
cytoprotective effects. However, since the virucidal condition exhibited some anti-entry
activity these results could also support the suggestion that AgNPs bind to the virus and
inhibit infection at an early stage (12, 21, 23, 33).
The entry inhibition results translated to a decrease in plaque formation,
indicating that the AgNPs affected the overall replication cycle of VACV whether
undergoing cytoprotective, virucidal or post-infection treatment with AgNPs (Figure 6).
The decrease in post-infection titer as compared to the control could be due to preventing
the spread of VACV after successful infection, as AgNPs were applied in the agarose
overlay, or this inhibition could be the result of an as yet unknown mechanism. AgNP
treatment did not cause increased viral titer, as assessed by plaque reduction assay, in any
conditions tested as was previously described with a similar Orthopoxvirus, MPV (34).
AgNPs were observed to decrease the mobility of G9 in a dose dependent fashion
(Figure 7). G9 is one of the nine proteins of the EFC considered to be an integral member
required for VACV entry. Furthermore, AgNPs altered the migration patter of the internal
control core protein, A4-GFP. These data suggest that AgNPs bind to the viral proteins of
VACV including the EFC. The shift observed in these experiments is small, ~ 1000 Da,
but consistent with the findings that polyacrylamide gel pore sizes are between 21 nm, for
gels with T = 10.5% and C = 5%, and 200 nm for gels with T = 4.6% and C =2 %,
respectively (42). Since these experiments were conducted with T = 10% and C = 3.3%,
values between those listed above, a 25 nm AgNP would likely pass through the pores,
between 21 and 200 nm by the experimental conditions, and generate a small shift as seen
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in Figure 7; however, precise pore sizes for these conditions are unknown. Additionally
complicating issues related to G9 western blotting is the difficulty of solubilizing G9 and
recovering enough protein to detect via western blot, which has been documented in the
literature (28). This difficulty was overcome by increasing the detergents, reducing
agents and time involved with lysate preparation; however, only low levels of the protein
were detectable which results in lesser G9 blot image quality in Figure 6, (top panel vs.
bottom). The observation that VACV direct fusion was mostly inhibited by virucidal
AgNP treatment, and not cytoprotective treatment, in conjunction with the observations
that AgNPs bind to G9, suggests that AgNPs could bind to VACV at the EFC and
prevent viral entry. These observations support AgNP inactivation of viral entry proteins
as one possible mechanism for AgNP antiviral activity. Additionally, these data are in
agreement with previous findings in the literature demonstrating that AgNPs bind to the
membrane bound proteins of viruses (12, 21). Alternatively, the shift in G9 could be a
result of the stringent conditions used to solubilize the G9 protein. The literature provides
no data concerning the fate of AgNPs subjected to the SDS-PAGE solubilization process,
so phenomena brought about during such a procedure could also explain G9’s mobility
shift. In future studies, extracting the proteins from the gel and running such assays as
mass spectrometry might provide a better clue as to if G9 is bound by AgNPs.
Cytotoxicity data suggest that AgNPs exert antiviral effects at non-toxic doses
(Figure 8). While the MTT data support a decreased metabolic state at higher doses
during a 4 hour exposure, microscopic evaluation, via the common and widely-used
trypan blue staining assay for cell membrane integrity, revealed that cells at 4 hours of
AgNP exposure excluded trypan blue. These results indicate that cellular membranes are
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intact (Supplemental Figure 2). Furthermore, the observation that all conditions at 24
hours of exposure to AgNPs were within the range of the untreated control suggest that
the cells recovered from the decreased metabolic state observed at 4 hours; if the cells
had been rendered non-viable by the AgNPs it is unlikely they would recover to the same
cell numbers and combined metabolic state of the untreated control as detected by the
MTT cytotoxicity assay at 24 hours. Since macropinocytosis is an active, energydependent process, the decreased metabolic state may be creating a general antiviral-state
for the target cell through the decrease in macropinocytosis brought on by decreased
metabolic function within the cells (35). Further investigation into this possible
mechanism of antiviral activity is warranted. Comparison of AgNPs used in this study
with cytotoxicity data present in the literature is a difficult task due to the multitude of
different AgNPs studied. Different AgNP characteristics such as size, shape, method of
synthesis and capping/stabilizing agent can drastically alter the biological interaction of a
nanomaterial (30, 47). Cytotoxicity values in the literature range from 0.7 μg mL-1 to
greater than 449 μg mL-1 (1, 20). AgNPs used in this study were not toxic at antiviral
concentrations suggesting they could be a potential therapeutic agent.
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CONCLUSIONS
This study examined two different sets of AgNPs and is the first of its kind to
establish a precise stage in viral infection at which AgNP-mediated antiviral activity
occurs. In addition to defining the stage at which AgNP antiviral activity occurs, the data
presented here suggest a mechanism for the observed virucidal activity. This virucidal
activity was observed in multiple species of virus in the literature and would suggest that
any number of virus species as yet unstudied in the context of AgNP antiviral activity
would be susceptible to inhibition. Additionally, observations made within this report
suggest at least one additional mechanism of AgNP antiviral activity. This additional
mechanism, seemingly linked to macropinocytosis and metabolism, may also be
responsible for the antibacterial properties of AgNPs. The suggested alternative
mechanism(s) would also have the potential to affect the infection process of many
different viral species, as there are in fact many different species that use cellular uptake
mechanisms to facilitate their infection processes. The fact that AgNPs can exhibit
multiple methods of antiviral activity, at non-cytotoxic concentrations, makes them
attractive as potential broad-spectrum antiviral therapeutics.
AgNPs were capable of mediating a dramatic reduction in VACV entry at noncytotoxic concentrations. The reduction in viral entry was observed in both cytoprotective
and virucidal capacity and was not due to the prevention of VACV adsorption to the host
cell. Furthermore, AgNPs were successful at mitigating viral entry via the direct fusion
and macropinocytosis-dependent entry pathways of VACV. The observations detailed
within this report suggest at least two mechanisms by which AgNP-mediated antiviral
activity occur. The virucidal aspect of AgNPs could be a result of the AgNPs binding to
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proteins such as the G9 subunit of the EFC and preventing their normal function to
facilitate viral entry or excess AgNPs in the AgNP/VACV infection mixture creating a
decreased metabolic state and reducing either VACV early gene expression or preventing
viral uptake via macropinocytosis. The AgNP cytoprotective observations demonstrate
that there may be an additional mechanism(s) by which AgNPs prevent viral entry and
infection. These additional mechanisms likely rely on a cellular response to AgNP
treatment such as concentration of AgNPs within macropinosomes during the maturation
process, decreased metabolism or a decrease in viral uptake via macropinocytosis
creating a general antiviral-state.
With the data collected here, in vivo studies of potential AgNP-mediated antiviral
applications are possible and justified. Due to the multiple mechanisms at play AgNPs
are uniquely suited for use as a stopgap treatment measure prior to identification of the
infectious agent(s) in cases of anticipated or probable viral exposure. Currently, there are
no truly broad-spectrum antiviral agents that can be used in such a manner. For airborne
pathogens one might envision AgNPs administered via inhalation to prevent viral
infection as they could offer virucidal effects for viruses that have not yet infected cells
and cytoprotective effects for viruses that have not yet infected cells or are bound to
airway tissues. There are currently no in vivo studies concerning AgNP antiviral activity
and very few in vivo studies concerning AgNP toxicity. With the finding of these studies,
such investigations are warranted.
AgNPs have the benefit of multiple possible methods for delivery since they are a
metal and resistant to changes in temperature and pressure unlike traditional antiviral
drugs. Evidence collected here and in other literature sources also suggest that AgNPs
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could mediate post exposure prophylaxis as well. AgNPs could also easily be used as a
disinfectant for contact spread pathogens on delicate surfaces such as sensitive equipment
and the skin. Furthermore, the use of AgNPs as a powder would be advantageous over
traditional liquid decontaminants, such as bleach, in the clean up of sensitive equipment
that would react poorly to liquid exposure. In each case the identity of the infectious
agent need not be known due to the multiple mechanisms at play, which mediate AgNP
antiviral activity and offer broad-spectrum antiviral activity.
Future investigation into the mechanisms of AgNP antiviral activity is necessary.
Additionally, in vivo investigation of potential AgNP antiviral applications is necessary.
All together, these data suggest that AgNPs could be a potent broad-spectrum antiviral
agent due to their multiple antiviral mechanisms.
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CHAPTER V:
DISCUSSION and CONCLUSION
DISCUSSION
Due to the exponential increase in biological applications for AgNPs, it is
important that key gaps in knowledge surrounding their use are addressed. Chapter II of
this dissertation sought to address the problems facing the manufacture of AgNPs for
their use as antimicrobial agents without unwanted side effects common to contemporary
AgNP synthesis and collection techniques. Developing a standard technology that is both
high throughput and capable of simultaneously measuring AgNP antiviral activity and
cytotoxicity is presented in Chapter III. A technology such as the one developed in
Chapter III would greatly benefit the screening of nanomaterials for antiviral activity by
enabling a automation of the process, standardizing the antiviral measurements and
simultaneous assessing cytotoxicity. The fourth chapter addresses the unknown
mechanisms involved in AgNP mediated antiviral activity by determining a stage at
which antiviral activity occurs and suggesting possible antiviral mechanisms of action.
Data presented here and in the literature suggest that AgNPs can be used as a new
class of broad-spectrum antiviral agents. These antiviral agents would have numerous
benefits over the traditional antiviral drugs and therapies. Since AgNPs are a metal there
would be no limitations on storage conditions or restrictions in their method of
application. Data presented here and in the literature concerning their ability to bind to
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and inhibit a number of different viral species would suggest that they are a true broadspectrum antiviral, therefore in the instance of suspected viral exposure or at the onset of
symptoms, a precise determination of the infectious agent is not necessary. Viral
resistance to AgNPs would also be less prevalent than in traditional specific antiviral
therapies due to the same non-specific biological interactions that grant AgNPs the ability
to inhibit many different viral species. Despite all these potential benefits, many issues
still surround the production of AgNPs, the screening of their antiviral potential against
different viral species, and the determination of their precise time point and mechanism
of antiviral activity.
In order to produce highly concentrated, biocompatible AgNPs with low
aggregation and narrow size distribution from a wet synthesis procedure, a tangential
flow ultrafiltration procedure was constructed and tested against the common
ultracentrifugation method for AgNP concentration. This procedure, which utilizes
hollow fiber modules with specific pore sizes to solutes within a solvent, was capable of
separating out a specific size population of naked AgNPs through upper and lower bound
filters for AgNPs synthesized via the Creighton Colloid method. Wet synthesis methods
of creating naked AgNPs, such as the Creighton method, produce a broad range of sizes,
which can be problematic as different size AgNPs can cause different biological reactions
(3, 10, 11). These differences are undesirable for the development of an antimicrobial
agent as differentiating between harming the host or the target microbe is complicated
due to the unknown effects caused by polydisperse AgNPs. The tangential flow
ultrafiltration procedure concentrated AgNPs to a level 13-fold higher than the original
colloid. This concentration effect is significant because the use of AgNPs as antiviral
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agents relies on the number of AgNPs available to bind to a target microbe, a
phenomenon less likely to occur in a less concentrated sample (24, 27, 37). Also, the
ability to size select and concentrate AgNPs creates a highly uniform population of
AgNPs that will increase antimicrobial efficacy and decrease unwanted side effects
brought on by polydispersity.
The tangential flow procedure for size selecting and concentrating AgNPs was
then compared to the common AgNP harvesting method of ultracentrifugation.
Tangential flow ultrafiltration was capable of concentrating AgNPs over 2.5-fold more
than standard ultracentrifugation. The AgNPs collected via ultracentrifugation
demonstrated a massive size distribution, high levels of aggregation and amorphous
shapes when compared to the filtered AgNP. The large size distribution and introduction
of various AgNP shapes would drastically affect normal biological processes which could
generate cytotoxic effects that would be interpreted as antiviral activity (3, 4). Multiple
reports detail the use of ultracentrifuged AgNPs for biological applications, such as the
detection of cancerous versus non-cancerous cells, cytotoxicity studies, and general blood
plasma screening for a variety of biomarkers (10). Any study employing
ultracentrifugation to purify or concentrate nanoparticles may introduce errors into the
data collected due to the different effects caused by a poly-disperse population of AgNPs,
such as those generated by ultracentrifugation (11). By using AgNPs prepared by
tangential flow ultrafiltration the likelihood of introducing errors based on AgNP polydispersity is abrogated. This method ensures that any measured antiviral activity is due to
the monodisperse, naked AgNPs themselves and not a function of contaminating
synthesis agents, size polydispersity, or aggregation.
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The findings of Chapter II indicate that tangential flow ultrafiltration is a
preferable method to the traditional method of ultracentrifugation for concentrating
AgNPs for use as antimicrobial agents. In addition to concentrating AgNPs, tangential
flow filtration is capable of size selecting AgNPs to generate a uniform, mono-disperse
population of AgNPs, while ultracentrifugation creates large aggregates and a large size
distribution of AgNPs. The large size distribution of AgNPs produced by
ultracentrifugation can introduce errors into data collected in the analysis of cytotoxicity
and antimicrobial activity. These variations in AgNP characteristics from different
synthesis techniques and concentration technique may cause other undocumented
biological reactions that occur upon exposure to AgNPs. Thus, minimizing the risk of a
diverse biological reaction from an AgNP population with broad size distribution is
preferable when developing an antimicrobial agent. The use of ultrafiltration to
concentrate other nanoparticles would provide a reliable, standardized method to reduce
variability when testing the antimicrobial of any nanoparticles In addition to size
selecting and concentrating AgNPs, this technique would work for any nanomaterial in
liquid phase. Because of the greater control over the physical characteristics of
nanomaterials, this filtering process will significantly advance the mobilization of
nanotechnology into consumer and therapeutic products as antiviral and antibacterial
agents.
Chapter III presents a standard, high-throughput method of testing nanomaterials
for antiviral activity to address the need for a standard antiviral screening method for
nanomaterials. Because traditional plaque assays are subjective and require large amounts
of time and money, a quicker high-throughput format for screening antiviral activity is
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desirable. Additionally, current techniques rely on performing cytotoxicity assays
separately from the antiviral testing. This separation can result in the masking of antiviral
activity by cytotoxicity, as well as double the amount of work, time and money required.
A large-scale HIV-1 mutation rate assay, based on colony forming units, was
chosen as the basis for developing the new high-throughput antiviral assay. This assay
utilized an HIV-1-based viral vector system that infects host cells and carries with it Hyg
resistance so that only infected cells will be viable after addition of selective medium
(14). The vector system was scaled down to a 96-well microtiter plate for ease of
automation and high-throughput antiviral screening with an endpoint measurement by the
standard MTT metabolic assay, a staple in the assessment of cell viability (6, 23, 25, 26).
Because this new assay employs a viral vector system, the glycoproteins incorporated
into the virion are interchangeable and thus multiple different viruses can be simulated
and screened via the same standard assay simply by interchanging the target virus’s entry
glycoprotein (8, 14). Standardization of antiviral screening was also established through
the use of MTT as the endpoint measurement. Many labs are already equipped with the
machinery and reagents required to conduct this assay and the National Cancer Institute’s
Nanotechnology Characterization Laboratory lists MTT as one of only two standard
methods for screening AgNP cytotoxicity (25, 35). Tetrazolium salts, such as MTT and
its chemical relatives, have different wavelengths at which they absorb and thus can be
interchanged to test different types of nanomaterials. This interchangeability is essential
because different nanomaterials exhibit different SPR wavelengths that might interfere
with the endpoint of the MTT (9, 19). By using different tetrazolium salts the assay
remains the same standard assay from nanomaterial to nanomaterial and by using the
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viral vector system the same standard assay can be used from virus to virus, affording a
standardization and flexibility lacking in current methods.
The new standard assay was then evaluated for its ability to accurately detect viral
titers through comparison with the traditional colony forming unit assay. Changes in viral
titers over three orders of magnitude were accurately measured by the new assay and
confirmed via colony forming unit assay. These data indicate that the new highthroughput assay is capable of detecting decreases in viral titer brought on by inhibition
of infection. To the author’s knowledge this assay is the first example of a viral colony
forming unit assay for antiviral activity in high-throughput, 96-well microtiter format.
Once the new assay was established to accurately measure viral titer and thus
inhibition of infection, AgNPs were used to gauge the assay’s ability to simultaneously
measure antiviral activity and cytotoxicity. The new assay demonstrated that AgNPs
clearly inhibited infection by the viral vector system. Furthermore, this antiviral activity
was not accompanied by AgNP cytotoxicity. Traditional colony forming unit assays and
reporter constructs are dependent on the living cells to gauge relative infectivity of a
virus. If the antiviral agent being screened kills the target cells, a false positive for
antiviral activity will be observed and interpreted as antiviral activity (36). The traditional
assays must typically be run twice for each antiviral agent concentration tested in order to
rule out possible toxicity; however, counting colonies can be a highly subjective process
and thus introduces a large variation into the data collected (2, 20). Running the
traditional assays in parallel to rule out possible cytotoxic effects add to the cost and time
involved with each experiment thus preventing these technologies from achieving highthroughput capabilities. Additionally, variations in cell number and MOI from assay to
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assay will further cloud the distinctions between antiviral activity and cytotoxicity. This
new assay eliminates the variations introduced in the traditional assays by permitting the
simultaneous measurement of antiviral activity and cytotoxicity in the same plate. The
viral vector system employed by this assay also permits a general indication of possible
antiviral mechanisms at work by limiting the infection cycle to the point of proviral gene
expression. Inhibition of the viral vector system can be interpreted as affecting the early
processes during infection, an ability not present in the use of wild type virus colony
forming unit assays which undergo all stages of viral replication. Inhibition of the viral
vector system in this new assay indicates that antiviral activity occurs at early time points
in infection and that AgNPs were observed to inhibit viral vector infection, this study is
in agreement with current literature that indicate viral inhibition by AgNPs occurs at an
early stage of viral infection (7, 17, 18, 29, 33, 34).
In Chapter III a new high-throughput screening assay was successfully developed
and found to simultaneously measure the antiviral activity and cytotoxicity of
nanomaterials in a cell culture-based system. This assay represents a new system by
which nanomaterials can be screened for antiviral activity in the absence of complications
masking antiviral effects. Additionally, due to the parameters of this assay such as the use
of MTT and interchangeable entry glycoproteins, this assay affords a level of
standardization lacking in the assessment of nanomaterials as antivirals. The results of
this assay can also serve as a “finger in the wind,” gauge from which the direction of
future mechanistic studies of nanomaterial antiviral activity. In the process of validating
this new assay with a contemporary nanomaterial, AgNPs showed clear antiviral effects
and low cytotoxicity. These data demonstrate a potential antiviral agent with a high
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therapeutic index. The AgNPs inhibited the virus at an early stage of replication prior to
assembly of new particles in the cell. Further investigation into the mechanism of
nanoparticle antiviral activity is warranted to determine if the AgNPs bind to the virus,
the AgNPs bind to the cell, or both, are responsible for antiviral activity.
The third objective of this manuscript, examined in Chapter IV of this manuscript,
hypothesized that AgNP mediated antiviral activity was the result of AgNPs preventing
viral entry. Two completely different sets of highly concentrated and uniform AgNPs
were used in this objective to pinpoint the stage of viral infection at which AgNP
antiviral activity occurs and illuminate possible mechanisms behind this inhibition, a vital
gap in knowledge concerning AgNP antiviral activity. VACV was chosen as the viral
system to examine AgNP-mediated antiviral activity and its possible mechanisms due to
the call to research by various governmental agencies and the growing concern for the
use of Variola major as a potential bioweapon.
Adsorption of VACV to host cells was examined in the first aim of objective three
to determine if AgNPs interrupted this process. AgNPs did not interfere with adsorption
to the host cell, indicating that either the cellular proteins or the VACV proteins
responsible for binding to host cells were unaffected by AgNPs. It is possible that the
large branched structure of the cellular GAGs, or their viral binding counterparts, are
unperturbed by the binding of AgNPs because this interaction is not dependent on a
conformational change but rather an electrostatic interaction (13). The binding of AgNPs
may not abolish this charge interaction or the AgNPs are capable of mimicking the
charges responsible for normal virus/host interaction, thus re-establishing any abolished
binding activity.

135

The effects of AgNPs on overall VACV entry, both direct fusion and
macropinocytosis-dependent entry, were then investigated. Two distinct sets of AgNPs
were found to significantly inhibit the entry process of VACV during β-gal entry assay at
4 hours. Confocal microscopic investigation at 1 hour post-infection confirmed the
findings of the β-gal entry assay. The AgNPs had both a cytoprotective and virucidal
effect on VACV measured by decreases in viral entry in both assays. These findings are
in agreement with the sources of literature that suggest AgNPs exert antiviral activity
occurs during early stages of viral infection. This study expanded on the literature
findings by pinpointing the precise stage of viral inhibition to the entry/fusion process (7,
17, 18, 29, 34). Additionally, AgNPs were observed binding the G9 protein of VACV’s
EFC through mobility shifts during Western blotting. The decrease in mobility supports
previous observations of AgNPs binding to viral entry proteins as a mechanism for their
virucidal activity (7). Inhibition of viral entry by AgNPs also translated to a decrease in
plaque formation, indicating that the prevention of viral entry by AgNPs affected the
overall replication cycle of VACV. This effect was observed whether undergoing
cytoprotective, virucidal or post-infection treatment with AgNPs. Importantly, AgNP
treatment did not cause increases in viral titer, as assessed by plaque assay, in any
conditions tested as was previously described (29).
Since VACV is known to enter cells via two distinct mechanisms, direct fusion and
macropinocytosis-dependent fusion, the third aim of this objective used Pak1 siRNA to
inhibit macropinocytosis and permit investigation into the AgNP affect on direct fusion
of VACV to the target cell. Pak1 was successfully knocked down to levels similar to
those found previously in the literature, at which macropinocytosis was inhibited (21).
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Under these conditions, cytoprotective treatment with AgNPs had almost no effect, which
indicates that inhibition of direct fusion of VACV by AgNPs might be prevented by the
AgNPs being too spaced out on the cell at the lower concentrations to adequately prevent
viral entry. Importantly, the cytoprotective effects of AgNPs might require
macropinocytosis to bring AgNPs and VACV into closer proximity, thus facilitating a
chance encounter and an inhibition of entry since AgNP uptake into cells is
macropinocytosis-dependent (1, 12). In the tubular domains of an endosome, which are
between 50-90 nm in diameter, a 25 nm particle, such as those used in this objective,
could occupy up to half of the macropinosome’s luminal space (22). In the vacuolar
lumen of a macropinosome, between 200-1,000 nm in diameter, a 25 nm AgNP would
occupy 2.5-12.5% of that diameter while a VACV virion, averaging 250-350 nm in
diameter, would occupy 25-35% of the that diameter (5, 22). While these values are
considering only two dimensions, the reduction in volume of the macropinosome as it
matures would increase the likelyhood of VACV encountering an AgNP. VACV could
then become trapped within the endosome and destroyed in the lysosome as a result of a
chance encounter with an AgNP during macropinosomal maturation (16). Supporting the
suggestion that AgNPs bind to the virus and inhibit infection at an early stage, virucidal
treatment of VACV elicited anti-entry effects on VACV’s direct fusion mechanism (7,
17, 18, 28).
These anti-entry effects by AgNPs were observed at non-cytotoxic concentrations of
AgNPs as demonstrated by MTT assay and trypan blue exclusion indicating that AgNPs
have a high therapeutic index. While the MTT assay showed decreased metabolic
function at high AgNP doses for 4 hours of exposure, microscopic evaluation revealed
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that cells at 4 hours of AgNP exposure were intact, excluding trypan blue. Combining the
results from the MTT assay and trypan blue assay suggests that the cells are intact though
experiencing a decreased metabolic state. Furthermore, the observation that all AgNP
treatments at 24 hours of exposure were within the range of the untreated control suggest
that the cells recovered from the observed decreased metabolic state at 4 hours. This
recovery could be the result of the AgNPs binding to their maximum amount of
biological material, thus creating the decline in metabolism. After the AgNPs have bound
all the biological material possible including cellular and viral proteins, the cells may
then regenerate the proteins inactivated by AgNP binding and thus accounting for the
rebound in metabolic status. Since macropinocytosis is an active, energy-dependent
process, the decreased metabolic state may also be creating a general antiviral-state for
the target cell through the decrease in macropinocytosis brought on by decreased
metabolic function within the cells (31). This decrease in metabolism and possible
reduction in macropinocytosis preventing viral entry may be part of a mechanism
responsible for the anti-entry effects of AgNPs.
Chapter IV demonstrated that AgNPs inhibit VACV infection by preventing viral
entry at non-cytotoxic concentrations. These effects were observed to occur at VACV
entry in both a cytoprotective and virucidal capacity. Furthermore, observations were
made that suggest multiple possible antiviral mechanisms of action. These possible
mechanistic observations are significant as previous studies assessed viral systems
covering more than one stage during viral infection or investigated the only the virucidal
activity of AgNPs. The results presented in this dissertation suggest AgNPs can be
described as viral entry inhibitors. Additionally, by examining both the virucidal and
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cytoprotective capacity of AgNPs, potent cytoprotective antiviral effects were observed
in Chapter IV. These cytoprotective effects could have even farther reaching potential as
these effects most likely rely on active uptake by the host cells and could possibly be
used to combat diseases associated with aberrant cellular uptake. These results lay down
a framework upon which further investigation into the development of AgNPs as an
antiviral agent and antiviral therapeutic is possible. Because AgNPs exhibited multiple
mechanisms of action against VACV, which exploits multiple mechanisms for entry,
AgNPs would be an ideal candidate as a new class of broad-spectrum antiviral agents.
CONCLUSIONS
Nanotechnology’s

presence

is

exponentially

increasing

in

commercial

applications. The applications of the most popular commercial nanotechnology AgNPs
range from use as antiviral agents to cutting edge biosensors. However, this technology is
still very young and requires better methods of generating AgNPs, better methods of
studying their antiviral properties and a greater understanding of how AgNPs exert
antiviral activity. The findings of these investigations suggest tangential flow
ultrafiltration is capable of generating a highly uniform set of AgNPs. With this process
more precise antimicrobial study is possible without the unwanted contaminants or
adverse biological reactions possible when using AgNPs prepared via traditional
methods. Additionally, other nanomaterials in the liquid phase can be concentrated and
size selecting using this technique. These studies also proposed the use of a novel assay
for screening nanomaterials for their antiviral potential. Tested with AgNPs, this assay
exhibited the unique potential to measure cytotoxicity and antiviral activity
simultaneously while enabling automation via its high-throughput format. AgNPs were
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found to have low cytotoxicity and high antiviral activity indicating they have a high
therapeutic index. This assay is also capable of screening other nanomaterials for
antiviral activity and cytotoxicity simultaneously. AgNPs were found exert potent
antiviral activity at non-cytotoxic concentrations with this new assay. Further
investigation into the time point and mechanism of AgNP antiviral activity were also
evaluated in these studies. AgNP antiviral activity was pinpointed to the entry stage of
VACV infection where AgNPs were found to have both cytoprotective and virucidal
effects at non-cytotoxic concentrations again suggesting that AgNPs have a high
therapeutic index. This work also observed multiple mechanisms by which AgNPs may
exert their antiviral properties. Because of the multiple methods of preventing viral entry,
AgNPs would be ideal for further development as broad-spectrum antiviral agents.
Future investigations into the antiviral activity of AgNPs can be divided up in the
three basic categories. These categories are immediate investigations to take place within
the next year, intermediate investigations to take place over the next five years, and long
term investigations to take place over the next ten years. The first immediate
investigation would concern the knockdown of Pak1 as discussed in Chapter IV. Because
the siRNA system designed against Pak1 was only capable of an 87% knockdown, some
Pak1 may be functional within the target cells. This unaffected Pak1 could then mediate a
low level of macropinocytosis, thus allowing some of the VACV virions to enter the
target cells via macropinocytosis-dependent fusion. A quantitative assay measuring
macropinocytosis via fluid phase marker, such as a fluorescent dextran or horseradish
peroxidase, would account for this possibility by generating a percent knockdown of
macropinocytosis in conjunction with Pak1 knockdown. Characterizing the specific
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decrease in macropinocytosis will enhance the data presented within this dissertation by
providing a context for the level of VACV direct fusion inhibition by AgNPs. For
example, if macropinocytosis is still occurs after Pak1 knockdown, a refined mechanism
for AgNP antiviral activity would be apparent because the inhibition seen in Figure 4
might be a result of AgNPs preventing fusion of virions contained within
macropinocytotic vesicles. This refined mechanism would place more emphasis on the
cytoprotective effect of AgNPs than on the virucidal potential of AgNPs.
The effects of AgNPs on fluid phase uptake could be determined as part of the
immediate investigations. Since a metabolic decline was observed at 4 hours of
incubation with AgNPs above 64 μg mL-1, macropinocytosis could be decreased as well
due to its dependence on the cell’s active metabolism. It would be vital to know if AgNPs
could mediate such an effect for the development of an antiviral agent as well as a
potential therapeutic for other diseases associated with aberrant macropinocytosis.
Transmission electron microscopy examination of cellular morphology and membrane
ultra-structure would also be useful in determining whether or not AgNPs are capable of
preventing macropinocytosis. AgNPs limiting macropinocytosis would represent yet
another mechanism by which AgNPs demonstrate antiviral activity. This antiviral activity
would likely be broad-spectrum as a number of different viral species gain access to their
target cells via macropinocytosis (22).
The decrease in MTT values at 4 hours of AgNP exposure followed by a rebound
to control levels at 24 hours of AgNP exposure suggests that AgNPs mediated a
temporary decline in metabolism. A better understanding of the cytotoxic properties of
AgNPs is required to understand if the decline in metabolism was beneficial to the cell by
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promoting a general antiviral state or if the decreased metabolism was due to damage
associated with AgNP exposure. If the AgNPs can induce a decreased metabolic state
from which the cells can recover, it would represent a novel form of broad-spectrum
antiviral agent. This mechanism of antiviral activity would be affective against any
possible viral pathogen due to the inhibition of early viral gene expression. Inhibition at
this stage of viral infection could possibly deny the virus time to establish a foothold
inside the cell and provide the immune system time react and effectively combat the
intruder. To further explore the potential cytotoxicity of AgNPs an assay for apoptosis, an
additional metabolic assay for viability and a necrosis assay could be used to determine
how AgNPs may negatively impact the target cell. These data could be collected easily
with an assay kit, such as ApoTox-Glo (Promega, # G6320, Madison, WI) containing all
three assays performed in the same well. Other assays could provide support to the kit
assay and build on its findings.

These additional assays could include a lactate

dehydrogenase leakage assay to determine cellular necrosis, caspase activation assays to
determine if AgNPs are causing apoptosis, ROS assays to determine if AgNPs are
mediating ROS production, and ATP:ADP quantification assays to determine if
mitochondrial function is impaired by AgNP exposure. Each of these assays could help to
pinpoint possible negative impacts of host cell exposure to AgNPs as well as suggest if
the AgNPs are capable of mediating an antiviral state due to decreased metabolism.
In combination with the above assays for possible cytotoxic effects mediated by
host cell exposure to AgNPs, a TEM analysis of AgNPs effects on cellular morphology
could also be conducted in the immediate investigations. Such a study would detail when
and where AgNPs were interacting with cells. For example, TEM could detect possible
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increased AgNP concentrations in a macropinosome or where AgNPs bound to cellular
membranes. By varying the time points at which samples were prepared for TEM a
chronological analysis of when AgNPs collect at various organelles within the cell is
possible. AgNP effects on cellular structure could also be determined and used to gauge
possible cytotoxic effects as well.
Based on the results generated by the quantitative macropinocytosis assay,
cytotoxicity assays, and TEM analyses, intermediate investigations utilizing different
target cells and viral strains would take place over the next five years. Different target
cells could be selected for either increased or decreased basal levels of macropinocytosis.
By studying viral entry in cell lines with varying levels of macropinocytosis a clearer
understanding of how AgNPs exert their cytoprotective inhibition of VACV is possible.
For example, in a cell line with higher levels of macropinocytosis, if VACV entry is
inhibited to a greater degree after cytoprotective treatment with AgNPs, it would suggest
that macropinocytosis is an active process required for AgNP-mediated anti-entry effects.
Additional cell lines genetically designed without genes vital for macropinocytosis may
also be a possibility for further examination of the mechanism behind AgNP effects on
viral entry. Each of these scenarios would provide needed insight into the mechanism of
AgNP-mediated inhibition of viral entry. These data would also shed light on possible
methods of AgNP administration as an antiviral agent.
Different viral VACV strains have demonstrated varying levels of dependence on
macropinocytosis for entry into the host cell (5, 28). Using a strain that primarily
accomplishes entry via direct fusion, one could more accurately determine the ability of
AgNPs to prevent this method of viral entry. Conversely, strains that primarily utilize
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macropinocytosis for entry into the host cell could be used to expand upon the research in
this dissertation and further explore factors impacting AgNP inhibition of
macropinocytosis dependent fusion such as AgNP dose, size, shape, and time of
exposure.
Examining other viral species’ susceptibility to AgNP-mediated inhibition of
entry would also be beneficial for the intermediate investigation term. A particularly
interesting virus system to examine AgNP antiviral activity would be the human
pathogens of the Mastadenovirus genus, including the respiratory pathogens of Human
adenovirus C. Unlike, the viruses in the literature that previously demonstrated
susceptibility to AgNPs, Adenoviruses do not have a lipid membrane, or envelope. A
result of Adenovirus inhibition would lend support to the broad-spectrum antiviral
activity of AgNPs as well as be the first such study of nanotechnology to prevent
Adenoviral infection. Other viral species could also be screened via the assay described
in Chapter III. By inserting the glycoproteins of other viruses into the HIV-1 vector
system a broad range of viral species could be simulated in a Biosafety-Level 2
condition, such as biodefense threat viruses Lassa virus and Ebola virus, both of which
have no approved antiviral treatment strategies. Each of these studies would also be the
first of their kind to test a nanotechnology-based antiviral agent with each respective
virus.
Further exploration into the time point of AgNP exposure, with respect to the
infection time point, and resulting antiviral effects is also warranted during the
intermediate investigation. In Chapter IV, AgNPs added after infection were capable of
inhibiting viral replication as measured by standard plaque assay. AgNPs could possibly
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mediate other antiviral activities associated with the multiple stages of viral replication
post entry. These replication effects could pertain to, but are not limited to, genetic
replication, viral morphogenesis and viral exit from the host cell. Finding additional
mechanisms of AgNP antiviral activity during these processes would justify continued
development of AgNPs as a novel broad-spectrum antiviral agent.
After examining AgNP antiviral activity in multiple viral species in vitro,
significant data would exist to justify an in vivo approach to examining antiviral activity
and cytotoxicity in the long term investigations. Very little data exist concerning AgNP
toxicity in vivo. Generating a series of data concerning AgNP dose tolerance, delivery
method, size effects and functionalization, such as targeting specific organs or increasing
bioavailablity through surface modifications of the AgNPs, would be essential steps in
exploring the potential use of AgNPs as antiviral agents. Additionally, there are no
studies available concerning the antiviral potential of any nanotechnology in vivo. A
mouse model would support a number of different viral infections and there are a
numerous reagents designed specifically for such studies. Such a model would also be
beneficial in determining the optimal method of AgNP delivery to prevent or treat viral
infections.
Due to the antiviral activity observed here and in the literature, AgNPs represent a
novel class of broad-spectrum antiviral agents. AgNPs would have many benefits
compared to other antiviral agents because they are a hearty metal and because of their
broad-spectrum antiviral activity. Since AgNP antiviral activity occurred at non-cytotoxic
concentrations, AgNPs would be further advantageous over current, toxic broad-spectrum
antivirals. With the methods for the accurate production and screening of nanomaterials
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also detailed within this manuscript, other nanoparticles can be quickly and accurately
screened for antiviral activity. All together this work suggests that AgNPs, and
potentially other nanomaterials, have a unique potential as a broad-spectrum antiviral
agents and therapeutics.
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